ПРОИЗВОДНЫЕ 1, 2, 4-ТИАДИАЗОЛИЯ, ФАРМАЦЕВТИЧЕСКИЕКОМПОЗИЦИИ НА ИХ ОСНОВЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ МЕЛАНОКОРТИНА

Настоящее изобретение относится к новым производным 1,2,4-тиадиазол-2-ия формулы (I), где R1, R2 и R4 представляют собой радикалы, содержащие циклические фрагменты, R3 обозначает водород, алкил, алкенил или алкинил, которые могут использоваться в качестве агонистов или антагонистов рецептора меланокортина. Также в настоящем изобретении представлена фармацевтическая композиция, обладающая активностью модулятора рецептора меланокортина, и способ ее получения. Целью настоящего изобретения является получение фармацевтических композиций, содержащих соединения, взятых в терапевтически эффективном количестве, а также фармацевтически приемлемый носитель, которые вводят субъекту, нуждающемуся в лечении заболеваний, опосредованных рецептором меланокортина, выбранных из группы, включающей такие нарушения, как метаболические нарушения, нарушения, связанные с ЦНС, и дерматологические нарушения, 7 н.з. и 14 з.п. ф-лы, 13 табл.

С-ГЛИКОЗИДНЫЕ ПРОИЗВОДНЫЕ И ИХ СОЛИ

Изобретение относится к новым соединениям - С-гликозидным производным и их солям где кольцо А представляет собой (1) бензольное кольцо, (2) пяти- или шестичленное моноциклическое гетероарильное кольцо, содержащее 1, 2 или 4 гетероатома, выбранных из N и S, за исключением тетразолов, или (3) ненасыщенный девятичленный бициклический гетероцикл, содержащий 1 гетероатом, представляющий собой О; кольцо В представляет собой (1) ненасыщенный восьми-девятичленный бициклический гетероцикл, содержащий 1 или 2 гетероатома, выбранных из N, S и О, (2) насыщенный или ненасыщенный пяти- или шестичленный моноциклический гетероцикл, содержащий 1 или 2 гетероатома, выбранных из N, S и О, (3) ненасыщенный девятичленный бициклический карбоцикл, или (4) бензольное кольцо; Х представляет собой связь или низший алкилен; где значения кольца А, кольца В и Х соотносятся таким образом, что (1) когда кольцо А представляет собой бензольное кольцо, кольцо В не является бензольным кольцом, или (2) когда кольцо А представляет ...

ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ АНИЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4

Изобретение относится к новым производным анилина общей формулы I, a также их фармацевтически приемлемым солям и изомерным формам, обладающим свойствами ингибиторов фосфодиэстеразы 4. Соединения могут найти применение, например, для усиления познавательной способности. В соединениях общей формулы I R1 означает С1-С4алкил, который является разветвленным или неразветвленным и который является незамещенным или замещенным одним или более галогеном, R2 означает С1-С4алкил, который является разветвленным или неразветвленным и который является незамещенным или замещенным одним или более заместителями ряда галоген, С1-С4алкокси или их комбинациями, С3-С10 циклоалкил, С4-С16циклоалкилалкил, в котором алкильный фрагмент содержит от 1 до 4 атомов углерода, С7-С11арилалкил, в котором арильный фрагмент содержит 6 атомов углерода, а алкильный фрагмент, который является разветвленным или неразветвленным, содержит от 1 до 5 атомов углерода, причем радикал арилалкил является незамещенным или замещенным ...

ТЕРАПЕВТИЧЕСКИЙ АГЕНТ ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА

Изобретение относится к новому терапевтическому лекарству для лечения диабета и включает соединение формулы I: R1-С(O)-C(R2 ')(R2)-Х-С(O)-R3, где Х представляет группу формулы -С(R4)(R5)-, -N(R6)-, -О-; где R4 - атом водорода, С1-С5 алкил, карбокси, фенил, C2-C5ацил, C2-C5алкоксикарбонил, R5 - атом водорода, C1-C5алкил; R6 - водород; R1 - фенил, необязательно замещен C1-C5алкилом, гидрокси, гидроксиалкилом, C2-C6алкенилом, ацилом, карбокси, тиенилом, C3-C7 циклоалкилом; бифенил, необязательно замещенный C1-C5алкилом или гидрокси; нафтил; терфенил; C3-C7циклоалкил, необязательно замещенный C1-C5алкилом или фенилом; необязательно замещенный C1-C5алкил; пиридил; бензотиенил; адамантил; инданил; флуоренил или группа ; R2 - водород, C1-C5алкил, необязательно замещенный карбокси; R2' - водород; R3 - C1 -C5алкил, необязательно замещенный фенилом или C1-C4алкокси; C1-C4алкокси; гидрокси; фенил; C3-C7циклоалкил, необязательно замещенный C1-C5алкилом; R2 и R7, взятые вместе, образуют группу -(CH2 ...

ПРОИЗВОДНЫЕ АМИНОМАСЛЯНОЙ, АМИНОПЕНТАНОВОЙ И АМИНОГЕКСАНОВОЙ КИСЛОТ

Изобретение относится к производным аминомасляной, аминопентановой и аминогексановой кислот общей формулы I где R1 - -COOR10; - (CH2)m-CONHOR10, -CONHNHR10, -(CH2)nSR50 или -Y-P (OR51)2; m = 0, 1, 2; n = 0-3; каждый из R2, R3, R4, R5, R6 и R7 независимо является водородом, С1-8 алкилом, С2-8 алкенилом, -OR11, -SR11, -NR12R13, Циклом 1, С1-8 алкилом, замещенным -OR11, -SR11, -NR12R13, -COR14, гуанидино или Циклом 1, или С2-8 алкенилом, замещенным -OR11, -SR11, -NR12R13, -COR14, гуанидино или Циклом 1, или R3 и R4, взятые вместе, представляют С1-8 алкилен, R5 и R6, взятые вместе, представляют С1-8 алкилен, R3 и R6, взятые вместе, представляют С1-8 алкилен, R2 и R3, взятые вместе, представляют С2-8 алкилен, R4 и R5, взятые вместе, представляют С2-8 алкилен или R6 и R7, взятые вместе, представляют С2-8 алкилен, или (1) R8 представляет собой 1) водород, 2) С1-8 алкил, 3) С1-8 алкоксикарбонил, 4) С1-8 алкил, замещенный -OR26, -SR26, -NR27R28 или -COR29, или 5) С1-8 алкоксикарбонил, замещенный ...

СИНТЕЗ КИСЛОРОДЗАМЕЩЕННЫХ БЕНЗОЦИКЛОГЕПТЕНОВ В КАЧЕСТВЕ ЦЕННЫХ ПРОМЕЖУТОЧНЫХ ПРОДУКТОВ ДЛЯ ПОЛУЧЕНИЯ ТКАНЕСЕЛЕКТИВНЫХ ЭСТРОГЕНОВ

Изобретение относится к новым промежуточным продуктам и усовершенствованному способу получения соединения С: Предлагаемый в изобретении способ получения основан на использовании недорогих исходных материалов, позволяет получать промежуточные продукты с высоким выходом и высокой степенью чистоты без необходимости проводить операции по хроматографической очистке и может быть реализован в условиях крупномасштабного промышленного производства. Изобретение относится к усовершенствованным способам получения соединения формулы I: соединения формулы II: соединения формулы III: соединения формулы VIII: соединения формулы IX: а также к реагенту, состоящему из трибромида бора и 2,6-диметилпиридина, для щадящего и селективного отщепления метильной группы в ароматических простых метиловых эфирах. 11 н. и 1 з.п. ф-лы.

ПРОИЗВОДНЫЕ ОКТАГИДРОНАФТАЛИНОКСИМА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ И СПОСОБ ИХ ПОЛУЧЕНИЯ

Производные октагидронафталиноксима пригодны для фармацевтической композиции ингибирующей расстройства, возникающие в результате нарушения баланса холестерина. Игибирование достигается в дозе 1-10 мг в день. Производные октагидронафталиноксима формулы I, где х-С1-C10-алкил; А-С1-С10-алкилен; R - водород; Y - водород, фенил, возможно замещенный заместителями, включающими: галоген С1 -С4-алкокси, или представляет гетероциклическую группу с 5 или 6 кольцевыми атомами, 1-3 из которых азот и/или кислород и/или сера. Гетероциклическая группа возможно замещена по крайней мере одним С1-C5-алкилом. Описывается фармацевтическая композиция для ингибирования биосинтеза/холестерина, где в качестве активного соединения она содержит соединение формулы I или его фармацевтически приемлемые соли или сложные эфиры в эффективном количестве. Предложен способ ингибирования расстройств, возникающих в результате нарушения баланса холестерина, путем введения млекопитающим соединение формулы I и способ получения ...

НОВЫЕ 4-(ГЕТЕРОЦИКЛОАЛКИЛ)БЕНЗОЛ-1,3-ДИОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНАЗ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЧЕЛОВЕКА, А ТАКЖЕ В КОСМЕТИЧЕСКИХ СРЕДСТВАХ

Настоящее изобретение относится к новым 4-(гетероциклоалкил)бензол-1,3-диольным соединениям, соответствующим общей формуле (I), приведенной ниже, в которой: R1, R2, R3 и R4, могут быть одинаковыми или различными, и представляют собой: - водород, - С-С-алкильный радикал, - гидроксиметил, гидроксиэтил, - (C-C-алкокси)карбонил, - С-С-алкокси, - гидроксил, или R1 и R2 связаны друг с другом и с атомом углерода, к которому они присоединены, с образованием углеродного цикла, содержащего 5 или 6 атомов углерода, а R3 и R4 могут быть одинаковыми или различными и представляют собой: - водород, - С-С-алкильный радикал, или R1 и R4 связаны друг с другом с образованием цепи -(СН)- или -(СН)-, а R2 и R3 могут быть одинаковыми или различными, и представляют собой: - водород, - C-С-алкильный радикал, Х представляет собой атом кислорода или атом серы, Y представляет собой водород, атом хлора или атом фтора, значение m может представлять собой 1 или 2, а значение n может представлять собой 0 или 1, и когда ...

N-ФЕНИЛАЛКИЛАЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ α -АМИНОКАРБОКСАМИДА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАКОЛОГИЧЕСКИ АКТИВНАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ПРЕДУПРЕЖДЕНИЯ РАЗВИТИЯ БОЛЕЗНИ

Изобретение относится к производным N-фенил-алкил-замещенного альфа-аминокарбоксамида формулы (1): где R - представляет собой фурил, тиенил, пиридил или незамещенный или замещенный фенил; A представляет собой -(CH2)m- или -(CH2)p-X-группу, в которой X является -O-, -S- или -NR4-; R1, R2, R3, R4, n, m, p определены в описании изобретения; и R5 и R6 независимо являются водородом или C1-C6-алкилом, и к их фармацевтически приемлемым солям. Указанные соединения обладают способностью к воздействию на центральную нервную систему, а поэтому могут быть использованы в качестве противоэпилептических средств, средств против паркинсонизма, нейрозащитных средств, антидепрессантов, спазмолитических и/или снотворных средств для лечения человека и животных. 5 с. и 3 з.п. ф-лы, 2 табл.

НОВЫЕ ПРОИЗВОДНЫЕ ВИНИЛКАРБОНОВОЙ КИСЛОТЫ И ИХ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ

... 1. Соединение общей формулы (I) где Х1 представляет собой арил или гетероарил, каждый из которых необязательно замещен одним или несколькими заместителями, выбранными из галогена, гидрокси, циано, амино или карбокси; или С1-6-алкила, С3-6-циклоалкила, С2-6-алкенила, С2-6-алкинила, арила, аралкила, гетероарила, гетероаралкила, С1-6-алкокси, С3-6-циклоалкокси, арилокси, аралкокси, гетероаралкокси, С1-6-алкилтио, арилтио, С3-6-циклоалкилтио, С1-6-алкилкарбонила, арилкарбонила, С1-6-алкилсульфонила, арилсульфонила, С1-6-алкиламидо, ариламидо, С1-6-алкиламинокарбонила, С1-6 -диалкиламинокарбонила, С1-6-алкиламино, С1-6-диалкиламино или С3-6-циклоалкиламино, каждый из которых необязательно замещен одним или несколькими заместителями, представляющими собой галоген; и Х2 представляет собой арилен или гетероарилен, каждый из которых необязательно замещен одним или несколькими заместителями, выбранными из галогена, гидрокси, циано, амино или карбокси; или С1-6-алкила, С3-6-циклоалкила, С2-6-алкенила ...

ПРОИЗВОДНЫЕ ПРОСТЫХ ПОЛИЭФИРОВ И ПЕНТАЦИКЛИЧЕСКИХ ГЕТЕРОЦИКЛИЧЕСКИХ ПОЛИМЕРОВ И ИХ ПРИМЕНЕНИЕ ДЛЯ КОМПЛЕКСООБРАЗОВАНИЯ С ИОНАМИ МЕТАЛЛОВ

Мономер представляет собой простой полиэфир, содержащий по крайней мере 3 эфирных фрагмента и пиррольные или тиофеновые фрагменты, соединенные с концами цепей этого полиэфира или через атомы углерода каждого из этих гетероциклических соединений в положениях 3,3' или более конкретно это относится к пиррольным группам, через его соответствующие атомы азота, положения 2 и 2' этих гетероциклов, однако являются свободными или самое большее замещены легко удаляемыми группами (например, защищающими группами). Применение для очистки от и извлечения ионов металлов, таких как радиоактивное серебро.

СПОСОБ ПОЛУЧЕНИЯ /S/-/+/-N,N-ДИМЕТИЛ-3-/1-НАФТАЛИНИЛОКСИ/-3-/2-ТИЕНИЛ/ПРОПАНАМИНА И ЕГО ФОСФОРНОКИСЛОЙ СОЛИ И ФОСФОРНОКИСЛАЯ СОЛЬ

Изобретение предоставляет стереоспецифический процесс синтеза (S)-(+)-N, N-диметил-3-(1-нафталинилокси)-3-(2- тиенил)-пропанамина, ключевого промежуточного продукта в синтезе дулоксетина.

СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ МЕТАБОЛИЧЕСКИХ ЗАБОЛЕВАНИЙ

... 1. Соединение формулы ! ! где m равно 1; n равно 1 или 2; t равно 0 или 1; и A представляет собой фенил, замещенный 2 группами, выбранными из галогена, алкила, содержащего 1 или 2 атома углерода, перфторметила и перфторметокси. ! 2. Соединение формулы ! ! где m равно 1; n равно 1 или 2; t равно 0 или 1; и A представляет собой фенил, замещенный 2 группами, выбранными из: галогена, алкила, содержащего 1 или 2 атома углерода, перфторметила и перфторметокси.

Способ получения простых эфиров или тиоэфиров бета-окси- или бета-бета'-диоксисульфонов линейного и циклического строения

Способ получения циклопропанкарбоксилатов

Способ получения производных этаноламина или их физиологически приемлемых солей или сольватов

Изобретение касается производных этаноламина, в частности получения соединений общей ф-лы Ar-CH(OH)-CH2-NHCH2-X-CH2-0-CH2-Y-Q . где Аг - 2-НО- СН2-4-НО-СбНз, 3,5-ди-ОН-СеНз, 3-СНз S(0)2-NH-4, НО-СбНз; X и Y - Ci-5-алкилен при условии, что общая сумма атомов углерода в X in Y лежит в пределах 5-7, a Q тиенил или 6н с-г-д й:н сн--сн-(:н при Z - кислород или сера, или физиологически приемлемых солей или сольвентов, которые могут быть использованы в медицине в качестве бронхорасширяющего средства . Цель - создание новых более активных веществ указанного класса. Синтез ведут алкилированием соединения ф-лы . II Аг- СН(ОН)-СН2МН2 соединений ф-лы III L- CH2-X-CH2-0-CH2-Y-0, где L- галрген или метансульфогруппа или п-толуолсульфони- локсигруппа. Целевой продукт выделяют в свободном виде, или в виде нужной соли, или сольвента. Новые вещества (в сравнении с известными)оказывают более продолжительное действие, что снижает необходимость их частого введения. 1 табл.

Способ получения основных эфиров енолов или их солей

Способ получения производных фенилпиперазина или их солей

Способ получения производных фенилпиперазина или их солей

Инсектицидное средство в форме эмульгируемого концентрата

ИНСЕКТИЦИДНОЕ СРЕДСТВО В ФОРМЕ ЭМУЛЬГИРУЕМОГО-КОНЦЕНТРАТА, содержащее активный ингредиент производное бензилового эфира 2,2димеТил-циклопропанкарбоновой кислоты , а также растворитель - ацетон или диметилформамид и эмульгатор алкиларилполигликолевый эфир, отличающееся тем, что, с целью повышения инсектицидной активности , оно содержит в качестве производного бензилового эфира 2,2диметил-циклопропанкарбоновой кислаты соединение формулы НзС снз ClzFC СОгК С1 где R - пентафторбензил или группа формулы где R- водород или фтор; СО а в качестве алкиларилполигликолевого эфира - нонилфеноллолигликблевый эфир, при следующем соотношении компонентов , мас.%: Активный ингредиент 20 Растворитель 60 Эмульгатор 20 ...

Hemmer der retroviralen Protease

Inhibitoren retroviraler Proteasen

NEUE CARBONSAEUREDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG SOWIE ARZNEIMITTEL, DIE DIESE VERBINDUNGEN ENTHALTEN.

Carboxylic acids of formula (I) and their salts, esters and amides are new: (In (I) R1 and R2 = opt. substd. aryl or heterocyclyl; A = satd. or unsatd. 1-10C alkylene opt. contg. an O, S or N atom (not bonded to unsatd. C) and opt. substd. byOH; Y = S, SO, SO2 or O; B = a direct bond or satd. or unsatd. 1-5C alkylene; provided that R1 and R2 are not both aryl).

THIOPHENDERIVAT UND VERFAHREN ZUR HERSTELLUNG.

VERFAHREN ZUR HERSTELLUNG VON 1,2-ETHANDIOLDERIVATEN UND DEREN SALZEN SOWIE MITTEL ZUR VERBESSERUNG DER CEREBRALFUNKTION MIT EINEM GEHALT DERSELBEN

VERFAHREN ZUR HERSTELLUNG ARALIPHATISCHER ALKOHOLE

PEPTIDDEFORMYLASEINHIBITOREN

NEUE VERBINDUNGEN UND DEREN VERWENDUNG ALS PPAR-MODULATOREN

INDANESSIGSÄURE-DERIVATE UND IHRE VERWENDUNG ALS PHARMAZEUTISCHE MITTEL SOWIE ZWISCHENPRODUKTE UND METHODEN ZU IHRER HERSTELLUNG

1,2-Ethandiolderivate und ihre Salze, Verfahren zu ihrer Herstellung und sie enthaltende gehirnfunktionsverbessernde Mittel.

1,2-Ethandiolderivate und ihre Salze, Verfahren zu ihrer Herstellung und sie enthaltende gehirnfunktionsverbessernde Mittel

Herstellung von N-Methyl-3-hydroxy-3-(2-thienyl)propanamin über neue carbamatgruppenhaltige Thiophenderivate als Zwischenprodukte

Es wird ein neuer Syntheseweg für N-Methyl-3-hydroxy-3-(2-thienyl)propanamin IV beschrieben, das als eine Ausgangsverbindung für die Herstellung von Duloxetin dienen kann. Die Synthese des N-Methyl-3-hydroxy-3-(2-thienyl)propanamins erfolgt über neue carbamatgruppenhaltige Thiophenderivate I und IIa als Zwischenprodukte. DOLLAR F1 ...

PHENYLBENZOESAEUREDERIVATE UND VERFAHREN ZU IHRER HERSTELLUNG

ISOTHIOHARNSTOFFDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE MITTEL

COMPOUNDS HAVING ANGIOTENSIN CONVERTING ENZYME INHIBITORY ACTIVITY AND DIURETIC ACTIVITY

VERFAHREN ZUR HERSTELLUNG VON 3-METHYLAMINO-1-(THIEN-2-YL)-PROPAN-1-OL

NEUE BENZAMIDE ALS PPATY-MODULATOREN

CYCLOPROPANCARBONSAEUREESTER, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS PESTIZIDE

Verfahren zur Herstellung von Organomagnesiumverbindungen

A PROCESS FOR THE PREPARATION OF NOVEL HETEROCYCLIC AMINOALCOHOLS

... 1,203,810. Heterocyclic amino-alcohols. DEUTSCHE GOLD - UND SILBERSCHEIDEANSTALT. 29 Dec., 1967 [30 Dec., 1966 (2)], No. 59037/67. Heading C2C. Novel compounds of formula in which the radicals R 1 -R 4 are H, halo, 1-6C alkyl, aralkyl, phenyl, OH, 1-6C alkoxy, nitro or 1-6C alkoxycarbonyl; R 5 and R 6 are H or methyl; R 7 and R 8 are H, halo, 1-6C alkyl, 1-6C alkoxy or phenyl; X is a mono- or bi-cyclic heterocyclic ring system having 1-4 heteroatoms, 5-6 ring members in each ring and which may contain one or more carbonyl groups and Y is O or a hydrogen atom and a hydroxyl group; their salts and quaternary ammonium derivatives are prepared by (1) reacting II with III in a solvent together with HCHO or a HCHO donor; (2) reacting IV or V with III; or (3) reacting VI with VII in the presence of a base followed in any of (1)-(3) by reduction of the oxo group to the hydroxy group if desired (R 9 and R 10 are 1-6C alkyl, W is halo and V is NH 2 -).

PROCESS FOR THE MANUFACTURE OF SYNTHETIC RESINS CONTAINING N-ACYLAMINO-ACID RESIDUES

... 1,216,247. Synthetic resins containing N- acylamino acid residues. FARBWERKE HOECHST A.G. 18 March, 1968 [17 March. 1967], No. 12910/68. Heading C3R. Synthetic resins containing N-acylamino-acid residues are obtained by reacting N-acylamino acid-(thiophen-2)-methyl esters with condensation products of phenol ethers and formaldehyde In Examples resins are obtained by reacting tert. - butyloxy - carbonyl - glycine - (thiophen-2)-methyl ester, tert.-butyloxy-L-leucine- [thiophen (2)-methyl]-ester, nitrophenyl-sulphenyl - L - alanine - [thiophen (2) - methyl] - ester and nitrophenyl - sulphenyl - L-leucine - [thiophen (2) - methyl] - ester with condensation products obtained from formaldehyde and resorcinol-dimethyl ether.

OPTICAL BRIGHTENERS

... 1445231 Detergent brightener composition; aryl-substituted butadienes HOECHST AG 9 Jan 1974 [12 Jan 1973] 00960/74 Headings C5D and C5E [Also in Division C2] Detergent compositions comprise a detergent and an optical brightener of formula wherein A is phenyl, naphthyl, 2-thienyl, or 2- furyl and B is 2-benzoxazolyl or a group as defined for A, and wherein A and B are unsubstituted or substituted by non-chromophoric groups. The compositions may comprise 0À01 to 2À0% by weight of the brightener. The detergent may be anionic, non-ionic or a mixture thereof. The compositions may comprise organic or inorganic builders, bleaching agents and foam stabilizers or inhibitors. 1 - Phenyl - 4[biphenyl -(41)] - butadiene - (1,3) is prepared by reacting biphenyl-(4)-methylphosphonic acid diethyl ester with cinnamic aldehyde in the presence of potassium tertbutylate. Compounds of the above formula wherein A is biphenylyl-(4), -naphthyl and #- naphthyl, and B is -naphthyl or #-naphthyl are prepared ...

Sensors for neutral molecules

SUBSTITUTED BENZAMIDES

THIENODIAZEPINE COMPOUNDS PROCESSES FOR PRODUCING THEM AND COMPOSITIONS CONTAINING THEM

... 1368812 Thienodiazepines SUMITOMO CHEMICAL CO Ltd 15 Nov 1971 [16 Nov 1970 15 Dec 1970 2 March 1971 (2)] 52891/71 Heading C2C Compounds of the general formula (R 1 = H, C 1-4 alkyl, cycloalkylmethyl, (CH 2 ) n - NR A R B , CH 2 CONR C R D , (CH 2 ) n OR E ; R A-E = H, C 1-4 alkyl; n = 1-4; R 2 = H, C 1-4 alkyl; R 3 = H, halogen; X = halogen, NO 2 , CN, C 1-4 alkyl or alkoxy) and their acid addition salts are prepared by (a) cyclizing a compound of the formula or salt thereof or (b) reacting a compound of the formula (R 4 = R 1 except H) with hydrazine hydrate, optionally followed by introduction of R 3 , R I and/or salt formation. The preparation of starting materials for both processes and of 2-bromoacetamido-3-(o-chloro- and fluorobenzoyl)thiophene is described. The above compounds are anticonvulsants, sedatives, muscle relaxants and hypnotics, and may be administered in the form of pharmaceutical preparations containing them in association with a carrier. Reference has been directed ...

Prostanoid compounds and their preparation and pharmaceutical formulation

Prostanoids are described of the formulae (and the salts thereof) in which: X is cis or trans - CH=CH- or CH2CH2-; R<1> is C1-7 alkyl terminated by -COOR<1><0> where R<1><0> is H, C1-6 alkyl or aralkyl; Y is a saturated heterocyclic amino group; and R<4> is aralkyl (in which the aryl portion is substituted by alkylthio, alkylsulphinyl, alkylsulphonyl, alkanoylamino, aroylamino, phenalkyl, aminosulphonyl, alkanoylaminosulphonyl, phenylsulphonyl, nitro, tetrazolyl, substituted phenyl or thienyl), or thienylalkyl or furnylalkyl in which the ring may be substituted. These compounds inhibit blood platelet aggregation and have bronchodilatory action, and may be formulated for use as anti-asthmatics and antithrombotic agents.

PROSTANOID COMPOUNDS AND THEIR PREPARATION AND PHARMACEUTICAL FORMULATION

AMINOCYCLOPENTANE ESTERS AND THEIR PREPARATION AND PHARMACEUTICAL FORMULATION

OLEFINE DERIVATIVES

Improved process for making 3-Methyl-2-Thiophene Carbaldehyde

... 1,176,312. 3 - Methyl - 2 - thiophene carbaldehyde. CHAS. PFIZER & CO. Inc. 16 Jan., 1968, No. 2431/68. Heading C2C. 3-Methyl-2-thiophene carbaldehyde is prepared by reacting 3-methylthiophene with dichloromethyl methyl ether in the presence of a Friedel-Crafts catalyst at a temperature of from 20‹ to 30‹ C. in a reaction-inert solvent.

ALKADIENYLCYCLOPROPANECARBOXYLATES

... 1389577 Pesticidal application of alkadienylcyclopropane - carboxylates SUMITOMO CHEMICAL CO Ltd 26 June 1972 [28 June 1971] 29842/72 Heading A5E [Also in Division C2] Pesticidal compositions comprise one or more esters of formula I: where R 1 -R 4 are H or CH 3 and R 5 is -CH 2 W or one of where R 6 is H or CH 3 ; R 7 is an alkenyl, alkadienyl, alkynyl or benzyl group; R 8 is H or an ethynyl or cyano group; R 9 is H, halogen or an alkyl group; R 10 may be the same as R 7 or halogen, thenyl, furyluralkyl, phenoxy, methyl-, methoxy-orchonine-substituted phenoxy or a phenylthio group; or R 9 and R 10 are joined to form a polymethylene chain optionally containing O or S; Y is O, S or -CH= CH-; n is 1 or 2; w is phthalimido, thiophthalimido, di- or tetra-hydrophthalimido or dialkylmaleimide; R 11 is phenyl, thionyl or furyl and x is a halogenation, together with an inert carrier. Synergistics for pyrethroids or other insecticides, and/or another insecticide, or a fungicide, nematocide, acaricide ...

ANISOTROPIC ORGANIC COMPOUNDS

Sensors for neutral molecules

Guanidine derivatives, processes for their production and pharmaceutical compositions containing them

Compounds of formula I, wherein R1, R2 and R3 are, independently, hydrogen, halogen or alkyl of 1 to 4 carbon atoms, and either R4 and R6 are independently hydrogen, alkyl or hydroxyalkyl, each of 1 to 4 carbon atoms, or alkoxyalkyl with a maximum of 6 carbon atoms, or R4 and R6 together signify dimethylene or trimethylene, R5 and R7 are, independently, hydrogen or alkyl of 1 to 4 carbon atoms, and X is sulphur, oxygen, imino, or (C1-4) alkylimino, are useful as antihypertensive agents.

PROCESS FOR THE PREPARATION OF THIENOPYRIDINE DERIVATIVES

SYN ISOMER 3,7 DISUBSTITUTED 3 CEPHEM 4 CARBOXYLIC ACID COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF

Malonamic acids and derivatives thereof as thyroidreceptor ligands.

Method of preparation of hydrocarbons aralkylic.

CYCLOPROPYLACETIC ACID DERIVATIVES

Glucocorticoid receptor modulators.

Insecticidal cyclopropyl-substituted di (aryl) compounds.

Compounds of the formula in which ar is substituted or unsubstituted phenyl, naphthyl, or thienyl; z is oxygen, sulphur, or menthylene and ar' is 2-methyl [1,1'-biphenyl]-3-y1, 3-phenoxy phenyl, 4-fluoro-3-phenoxyphenyl, or 6-phenoxy-2-pyridyl exhibit pyrethroid-like insecticidal and acaricidal activity and are relatively harmless to aquatic fauna.

Cyclopropylacetic acid derivatives.

Novel 2-(2,2-difluorocyclopropyl)-acetic acid derivatives of formula i wherein a is oxygen or -nr1- b is c2-c6alkylene, d id oxygen, sulfur or -o-ch2-, e is phenyl;phenyl substituted by from one to three substituents selected from the group halogen, c1-c4alkyl, c1-c3haloalkyl and c1-c4alkoxy; a five-membered aromatic heterocycle having from one tothree hetero atoms selected from the group nitrogen,oxygen and sulfur, a five-membered aromatic heterocycle having from one to three hetero atoms selected from the group nitrogen, oxygen and sulfur that is substituted by one or two substituents selected from the group halogen, c1-c4alkyl and c1-c3-haloalkyl; a six-membered aromatic heterocycle having from one to three nitrogen atoms; or a six-membered aromatic heterocycle having from one to three nitrogen atoms that is substituted by one or two substituted by one ot two substituents selected from the group halogen, c1-c4alkyl and c1-c3 haloalkyl, l is halogen or methyl, n is 0, 1 or 2 and r1 is ...

Malonamic Acids And Derivatives Thereof As Thyroid Receptor Ligands.

The present invention relates to novel thyroid receptor ligands and, more particulary, relates to malonamic acids and derivatives thereof formula (1), which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depresssion and osteoporosis. The present invention also provide methods, pharmaceutical compositions and kits for treating such diseases and disorders.

INSECTICIDAL CYCLOPRORYL-SUBSTITUTED DI(ARYL)COMPOUNDS

Glucocorticoid receptor modulators

CYCLOPROPYLACETIC ACID DERIVATIVES

Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars

Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars

"Insecticidal cyclopropyl-substituted di(aryl) compounds".

Orally active antiral compounds.

New esters of acids cyclopropanecarboxylic.

Glucocorticoid receptor modulators.

Dihalopropene compounds insecticidal/acaricidal agents containing same and intermediates for their production

New méthoxy-5 alcoyl ommonium tétrahydrofuranes and tétrahydrothiophénes, a process for their preparation and compositions therapeutic while containing.

D-cis, trans-chrysanthemates and insecticidal compositions the container.

New sulphides of N-substituted (a)-carbamoyle asymmetrical, their method of preparation and their application like insecticides and acaricides.

New sulphides of N-substituted (a)-carbamoyle asymmetrical, their method of preparation and their application like insecticides and acaricides.

Derived from phénylpipérazine.

Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars

Malonamic acids and derivatives thereof as thyroid receptor ligands

Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars

INSECTICIDAL CYCLOPRORYL-SUBSTITUTED DI(ARYL)COMPOUNDS

Glucocorticoid receptor modulators

Glucocorticoid receptor modulators

Malonamic acids and derivatives thereof as thyroid receptor ligands

PIPERAZIN DERIVATIVES

PROCEDURE AND INTERMEDIATE FOR THE PRODUCTION OF RETROVIRALEN PROTEASEHEMMERN

N- (1-DIMETHYLAMINOCYCLOALKYL) METHYL BENZAMID DERIVATIVES

PROCEDURE FOR THE CATALYTIC HYDROGENATION OF CARBON HETERO ATOMIC DOUBLE BONDS

AMIN-1,2 AND -1,3-DIOLVERBINDUNGEN AND THEIR USE FOR THE TREATMENT OF ALZHEIMER ILLNESS

MALONIC ACID AMIDES AS WELL AS THEIR DERIVATIVES AS THYROIDREZEPTOR LIGANDS

NEUE SUBSTITUIERTE BENZAMIDE, VERFAHREN ZU IHRER HERSTELLUNG UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE BENZAMIDE ENTHALTEN

Novel substituted benzamides of the formula XXI wherein R1, R2, R3, R4, R5 and A are as defined herein are useful in the treatment of emesis, and particularly chemotherapy-induced emesis in cancer patients. Some of the compounds are also useful in disorders relating to impaired gastric motility.

NAPHTHALEN CONNECTIONS, PROCEDURES FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL COMPOSITIONS

N (ARYL/CHETERO ARYL/CALKYL ACETYL) AMINO SAÜRE of AMIDES, PHARMACEUTICAL COMPOSITIONS AND TO METHOD-TO INHIBIERUNG BETA AMYLOID PEPTID RELEASE OR SYNTHESIS

CARBAMATE OF 2-HETEROZYKLISCHEN 1,2-ETHANDIOLEN

PROCEDURE FOR the PRODUCTION OF 2 (2-THENOYLTHIO) - PROPIONYLGLYCIN

VITAMIN D REZEPTORMODULATOREN OF THE PHENYL THIOPHEN TYPE

Method for synthesis of secondary alcohols

A method for synthesis of secondary alcohols is provided for pharmaceutical secondary alcohol by addition of organoboronic acids with aldehydes in presence of the cobalt ion and bidentate ligands as the catalyst. In addition, an enantioselective synthesis method for secondary alcohols is also herein provided in the present invention. The present invention has advantages in using less expensive cobalt ion and commercially available chiral ligands as the catalyst, wide scope of organoboronic acids and aldehydes compatible with this catalytic reaction and achieving excellent yields and/or enantiomeric excess.

STRUCTURE, SYNTHESIS, AND APPLICATIONS FOR POLY (PHENYLENE) ETHYNYLENES (PPEs)

The present disclosure provides novel poly(phenylene ethynylene) (PPE) compounds, methods for synthesizing these compounds, and materials and substances incorporating these compounds. The various PPEs show antibacterial, antiviral and antifungal activity. 2. The poly-(phenylene ethynylene) of wherein A and B=CCH claim 1 , C is not present claim 1 , X claim 1 , Y claim 1 , and Z=H and Z=O(CH)(CHN)CH.3. The poly(phenylene ethynylene) of wherein A and B=CCH claim 1 , C is not present claim 1 , X claim 1 , Y claim 1 , and Z=H and Z=O(CH)SO.4. The poly(phenylene ethynylene) of wherein A and B=CCH claim 1 , C is not present claim 1 , X and Y=H claim 1 , Z=O(CH)N(CH) claim 1 , and Z=(OCHCH)OCH.5. The poly(phenylene ethynylene) of wherein k=6.6. The poly(phenylene ethynylene) of wherein A and B=CCH claim 1 , C is not present claim 1 , X and Y=H claim 1 , Z=O(CH)N(CH) and Z=(OCHCH)OCH.7. The poly(phenylene ethynylene) of wherein A=CCHS claim 1 , B=CCH claim 1 , C is not present claim 1 , X and Y=H claim 1 , Z=O(CH)N(CH) and Z=H.8. The poly(phenylene ethynylene) of wherein A and B=CCH claim 1 , C=CH claim 1 , X=[CCH]COOCHCH claim 1 , Y=COOCHCH claim 1 , Z=O(CH)N(CH) and Z=H.9. The poly(phenylene ethynylene) of wherein A and B=CCH claim 1 , C=CH claim 1 , X=[CCH]COOCHCH claim 1 , Y=COOCHCH claim 1 , Z=O(CH)(CHN)CH and Z=H.10. The poly(phenylene ethynylene) of wherein A=CCHS claim 1 , B=CCH claim 1 , C=CH claim 1 , X=[CCH]COOCHCH claim 1 , Y=COOCHCH claim 1 , Z=O(CH)N(CH) and Z=H.11. The poly(phenylene ethynylene) of wherein k=3.12. The poly(phenylene ethynylene) of wherein the poly(phenylene ethynylene) exhibits biocidal activity.13. The poly(phenylene ethynylene) of wherein the poly(phenylene ethynylene) exhibits antiviral activity.14. The poly(phenylene ethynylene) of wherein the poly(phenylene ethynylene) exhibits antifungal activity.15. The poly(phenylene ethynylene) of functionally attached to a material or substance so that the poly(phenylene ethynylene) can interfere ...

HETEROCYCLIC RESORCINOL DERIVATIVES, PREPARATION OF SAME AND COSMETIC USES THEREOF

The invention relates to a compound of general formula (I) 2. The compound in accordance with claim 1 , characterized in that Ris a methyl group.3. The compound in accordance with claim 1 , characterized in that Ris a heteroaromatic single-ring claim 1 , preferably with 5 or 6 members.4. The compound in accordance with claim 1 , characterized in that Ris selected from the group consisting of a pyridine claim 1 , thiophene and thiazole heterocycle.5. The compound in accordance with claim 1 , characterized in that Ris a methyl group and Ris selected from the group consisting of 3-pyridyl claim 1 , 4-pyridyl claim 1 , 2-furyl claim 1 , 3-furyl claim 1 , 2-thiophenyl claim 1 , 3-thiophenyl claim 1 , and 2-thiazolyl.6. The compound in accordance with claim 1 , characterized in that it is selected from one of the following compounds:4-(1-(pyridin-2-yl)ethyl)benzene-1,3-diol;4-(1-(pyridin-3-yl)ethyl)benzene-1,3-diol;4-(1-(pyridin-4-yl)ethyl)benzene-1,3-diol;4-(1-(thiophene-2-yl)ethyl)benzene-1,3-diol;4-(1-(thiophene-3-yl)ethyl)benzene-1,3-diol;4-(1-(thiazol-2-yl)ethyl)benzene-1,3-diol;4-(1-(1-methyl-1H-benzo[d]imidazol-2-yl)ethyl)benzene-1,3-diol;4-(1-(1-methyl-1H-indol-2-yl)ethyl)benzene-1,3-diol;4-(1-(benzo[1)]thiophene-2-yl)ethyl)benzene-1,3-diol;4-(1-(thiophene-2-yl)butyl)benzene-1,3-diol;4-(3-methyl-1-(thiophene-2-yl)butyl)benzene-1,3-diol.7. A compound as defined in accordance with claim 1 , for use as a cosmetic active ingredient.8. A compound as defined in accordance with claim 1 , for use as a drug.9. A compound as defined in accordance with claim 1 , for use as a depigmenting active ingredient.10. A compound as defined in accordance with claim 1 , for use as an antioxidant active ingredient.11. A pharmaceutical or cosmetic composition claim 1 , characterized in that it includes as active ingredient at least one compound of formula (I) such as defined in accordance with in combination with a pharmaceutically or cosmetically acceptable excipient.13. The cosmetic ...

Compounds for the treatment of neurodegenerative diseases

Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies. 2. A method of disrupting or inhibiting the formation claim 1 , deposition claim 1 , accumulation claim 1 , or persistence of tau fibrils and/or aggregates claim 1 , comprising administering a therapeutically effective amount of the compounds of .3. The method of claim 2 , where the compound administered is in an amount between 0.1 mg/Kg/day and 1000 mg/Kg/day.4. The method of claim 2 , where the compound is administered in an amount between 1 mg/Kg/day and 100 mg/Kg/day.5. The method of claim 2 , where amount of compound administered is in an amount between 10 mg/Kg/day and 100 mg/Kg/day.6. A method resulting in neuroprotection from a tauopathy in a mammal comprising the step of administrating a therapeutically effective amount of a compound of .7. An article of manufacture claim 1 , comprising packaging material claim 1 , the compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , contained within packaging material claim 1 , which is used for treating the formation claim 1 , deposition claim 1 , accumulation claim 1 , or persistence of tau fibrils and/or aggregates claim 1 , and a label that indicates that the compound or pharmaceutically acceptable salt thereof is used for treating the formation claim 1 , deposition claim 1 , accumulation claim 1 , or persistence of tau fibrils and/or aggregates.8. A composition comprising the compound of and at least one pharmaceutically acceptable excipient.9. A method of treating a tauopathy in a mammal comprising the step of administrating a therapeutically effective amount of a compound of .10. The method of wherein the tauopathy is selected from the group consisting of Alzheimer's disease with neuronal and glial tau deposition claim 9 , Pick's disease claim 9 , progressive supranuclear palsy claim 9 , corticobasal degeneration claim 9 , familial frontotemporal dementia ...

NOVEL ORGANIC COMPOUND

The present invention provides an organic compound to be used in an electrochromic device. The organic compound has excellent oxidation-reduction repeating characteristics and shows high transparency in the bleached state without showing light absorption in the visible light region. The organic compound has a structure represented by Formula [1] according to Claim . In Formula [1], Aand Arepresent substituents, and at least one of Aand Ais an alkyl group having 1 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, or an optionally substituted aryl group. Rrepresents a substituent, X represents an electrochromic portion, and n is an integer of 1 to 3. 2. The organic compound according to claim 1 , wherein at least one of Aand Ais an alkoxy group having 1 to 20 carbon atoms.3. The organic compound according to claim 2 , wherein at least one of Aand Ais a methoxy group or an isopropoxy group. The present invention relates to a novel electrochromic organic compound.Various materials have been reported as electrochromic (hereinafter may be abbreviated as “EC”) materials of which optical absorption properties (colored state and light transmittance) are changed by an electrochemical oxidation-reduction reaction.Though metal oxides such as WOare known as inorganic EC materials, the method of forming a film from such a metal oxide is limited to, for example, deposition, which disadvantageously prevents formation of a large-size film.Organic EC materials are described in, for example, PTL 1 disclosing an EC device including a conductive polymer and PTL 2 disclosing an EC device including an organic low-molecular-weight compound such as viologen.The conductive polymer described in PTL 1 can be directly formed as an EC layer on an electrode by electropolymerization of a monomer. As the conductive polymer that forms the EC layer, for example, polythiophene, polyaniline, and polypyrrole are known.In these conductive polymers, the π-conjugated chain length of the main ...

FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM

The fluorine-containing ether compound is represented by the following formula (1): R-R—CH—R—CH—R. In the formula (1), Ris represented by the following formula (2), Ris represented by the following formula (3), Ris a perfluoropolyether chain, and Ris an organic end group different from R-R- and contains two or three polar groups, wherein each polar group is bonded to a different carbon atom, and the carbon atoms to which the polar groups are bonded are bonded to one another via a linking group containing a carbon atom to which the polar group is not bonded. In the formula (2), r is 1 to 3. In the formula (3), w is 2 or 3. 2. The fluorine-containing ether compound according to claim 1 , wherein all the polar groups of Rin the formula (1) are hydroxyl groups.7. The fluorine-containing ether compound according to claim 1 , wherein r is 2.8. The fluorine-containing ether compound according to claim 1 , wherein a number average molecular weight is in the range of 500 to 10000.9. A lubricant for magnetic recording media claim 1 , comprising the fluorine-containing ether compound according to .10. A magnetic recording medium in which at least a magnetic layer claim 1 , a protective layer claim 1 , and a lubricant layer are sequentially provided on a substrate claim 1 , wherein the lubricant layer contains the fluorine-containing ether compound according to .11. The magnetic recording medium according to claim 10 , wherein an average film thickness of the lubricant layer is 0.5 nm to 2 nm. The present invention relates to a fluorine-containing ether compound suitable for use as a lubricant for magnetic recording media, a lubricant for magnetic recording media containing the same, and a magnetic recording medium.This application claims priority under Japanese Patent Application No. 2018-170365 filed Sep. 12, 2018, the contents of which are incorporated herein by reference.In recent years, as information processing capacity increases, various information recording ...

METHOD FOR PRODUCING 1,2,4-OXADIAZOLE DERIVATIVE

The invention provides a production method of a 1,2,4-oxadiazole derivative represented by formula (A), which comprises reacting a compound represented by formula (B) and a compound represented by formula (C) in the presence of a basic compound: 3. The method according to claim 2 , wherein the compound represented by the formula (G) is subjected to an oxidation reaction to obtain the compound represented by the formula (B) claim 2 , and the obtained compound is reacted with the compound represented by the formula (C).5. The method according to claim 1 , wherein Ar is a phenyl group or a phenyl group having substituent(s).6. The method according to claim 1 , wherein the reaction of the compound represented by the formula (B) and the compound represented by the formula (C) is performed in the presence of a solvent.7. The method according to claim 1 , wherein the reaction of the compound represented by the formula (B) and the compound represented by the formula (C) is performed with dehydration.8. The method according to claim 1 , wherein the compound represented by the formula (B) is reacted in an amount exceeding 1 mol claim 1 , per 1 mol of the compound represented by the formula (C).9. The method according to claim 1 , wherein the basic compound is at least one inorganic basic compound selected from the group consisting of an alkali metal carbonate claim 1 , an alkaline-earth metal carbonate claim 1 , an alkali metal hydroxide and an alkaline-earth metal hydroxide.10. The method according to claim 9 , wherein the inorganic basic compound is used in an amount of 2 mol or less claim 9 , per 1 mol of the compound represented by the formula (C).11. The method according to claim 1 , wherein the basic compound is an organic basic compound claim 1 , and the organic basic compound is used in an amount of 0.3 mol or more claim 1 , per 1 mol of the compound represented by the formula (C).12. The method according to claim 1 , wherein the compound represented by the formula (C ...

Composition and Method for Making Oligo-Benzamide Compounds

The present invention includes compound compositions and methods of making compounds that include an oligo-benzamide compound having at least two optionally substituted benzamides. 212-. (canceled)14. The composition of claim 13 , further comprising one or more of diluents excipients claim 13 , active agents claim 13 , lubricants claim 13 , preservatives claim 13 , stabilizers claim 13 , wetting agents claim 13 , emulsifiers claim 13 , salts for influencing osmotic pressure claim 13 , buffers claim 13 , colorings claim 13 , flavorings claim 13 , aromatic substances claim 13 , penetration enhancers claim 13 , surfactants claim 13 , fatty acids claim 13 , bile salts claim 13 , chelating agents claim 13 , colloids and combinations thereof.15. The composition of claim 13 , wherein the pharmaceutical composition is in the form of a solution claim 13 , an emulsion claim 13 , a liposome-containing formulation claim 13 , a tablet claim 13 , a capsule claim 13 , a gel capsule claim 13 , a liquid syrup claim 13 , a soft gel claim 13 , a suppository claim 13 , an enema claim 13 , a patch claim 13 , an ointment claim 13 , a lotion claim 13 , a cream claim 13 , a gel claim 13 , a drop claim 13 , a spray claim 13 , a liquid or a powder.19. The compound of claim 18 , wherein R1 claim 18 , R2 claim 18 , R3 claim 18 , R4 claim 18 , R5 claim 18 , R6 claim 18 , R7 claim 18 , R8 claim 18 , and R9 may individually comprise an acetyl group or a t-butoxycarbonyl group claim 18 , a benzyl group claim 18 , a methyl group claim 18 , a substituted benzyl group claim 18 , a 4-fluorobenzyl group claim 18 , a 2-naphthylmethyl group claim 18 , or an amino acid claim 18 , an amino acid analogue claim 18 , an artificial amino acid claim 18 , a carbohydrate claim 18 , a lipid claim 18 , a nucleic acid claim 18 , a sugar claim 18 , or a linker.20. The compound of claim 18 , wherein R1 comprises an acetyl group claim 18 , R2 comprises a benzyl group claim 18 , R3 comprises an isopropyl claim 18 , and ...

FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND MANUFACTURING METHOD THEREOF

The present specification relates to a fullerene derivative, an organic solar cell including the same, and a fabricating method thereof. 3. The fullerene derivative of claim 1 , wherein m is 0.4. The fullerene derivative of claim 1 , wherein m is 1.5. The fullerene derivative of claim 1 , wherein at least one of the substituents of the hydrocarbon ring formed by the adjacent substituents of R1 to R10; and R5 to R8 is -(L)a-(M)b.6. The fullerene derivative of claim 1 , wherein a is an integer of 0 or 1; andL is a substituted or unsubstituted alkylene group having 1 to 4 carbon atoms; or a substituted or unsubstituted phenylene group.7. The fullerene derivative of claim 1 , wherein R is a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms; a substituted or unsubstituted alkoxy group having 1 to 20 carbon atoms; a substituted or unsubstituted cycloalkyl group having 3 to 60 carbon atoms; a substituted or unsubstituted cycloalkoxy group having 3 to 60 carbon atoms; a substituted or unsubstituted arylalkoxy group having 7 to 50 carbon atoms; a substituted or unsubstituted aryl group having 6 to 60 carbon atoms; a substituted or unsubstituted aryloxy group having 6 to 60 carbon atoms; a substituted or unsubstituted heteroaryl group having 2 to 60 carbon atoms claim 1 , which includes one or more of N claim 1 , O and S atoms; or a substituted or unsubstituted heteroaryloxy group having 2 to 60 carbon atoms claim 1 , which includes one or more of N claim 1 , O and S atoms.8. The fullerene derivative of claim 1 , wherein R is a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms; a substituted or unsubstituted alkoxy group having 1 to 20 carbon atoms; a substituted or unsubstituted arylalkoxy group having 7 to 50 carbon atoms; a substituted or unsubstituted aryl group having 6 to 60 carbon atoms; or a substituted or unsubstituted heteroaryloxy group having 2 to 60 carbon atoms claim 1 , which includes one or more of N claim 1 , O and S ...

FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIA, AND MAGNETIC RECORDING MEDIUM

A fluorine-containing ether compound represented by R—R—CH—R—CH—R—Ris provided. (Ris a perfluoropolyether chain; Rand Rare each independently any one of an alkyl group that may have a substituent, an organic group having at least one double bond or at least one triple bond, and a hydrogen atom; and —R—CH—Ris represented by Formula (2), and R—CH—R— is represented by Formula (3)) 2. The fluorine-containing ether compound according to claim 1 ,wherein the alkyl group that may have a substituent is an alkyl group having 1 to 6 carbon atoms, wherein the alkyl group includes a hydroxyl group or a cyano group.3. The fluorine-containing ether compound according to claim 1 ,wherein the organic group having at least one double bond or at least one triple bond is any one of a group containing an aromatic ring, a group containing a heterocyclic ring, an alkenyl group, and an alkynyl group.4. The fluorine-containing ether compound according to claim 1 ,{'sup': '3', 'claim-text': {'br': None, 'sub': 2', '2', '2', 'm', '2', 'n', '2, '—CFO—(CFCFO)—(CFO)—CF—\u2003\u2003(8)'}, 'wherein Rin Formula (1) is represented by any one of Formulas (8) to (10).'} {'br': None, 'sub': 3', '3', '2', 'y', '3, '—CF(CF)—(OCF(CF)CF)—OCF(CF)—\u2003\u2003(9)'}, '(m and n in Formula (8) represent average polymerization degrees, and each represent 0 to 30, with a proviso that m or n is 0.1 or more)'} {'br': None, 'sub': 2', '2', '2', '2', '2', 'z', '2', '2, '—CFCFO—(CFCFCFO)—CFCF—\u2003\u2003(10)'}, '(y in Formula (9) represents an average degree of polymerization and represents 0.1 to 30)'}(in Formula (10), z represents an average degree of polymerization and represents 0.1 to 30).5. The fluorine-containing ether compound according to claim 1 ,wherein a number-average molecular weight thereof is in a range of 500 to 10000.6. A lubricant for magnetic recording media claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the fluorine-containing ether compound according to .'}7. A magnetic ...

CHAIN MULTIYNE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF

The present invention relates to fields of organic chemistry and organometallic chemistry. The present invention discloses a chain multiyne compound, a preparation method thereof and an application in synthesizing a fused-ring metallacyclic compound. A structure of the chain multiyne compound in the present invention is shown as Formula I below. The present invention also provides a preparation method of the chain multiyne compound and an application thereof in a synthesis of a fused-ring metallacyclic compound. The chain multiyne compound disclosed in the present invention has multiple functional groups and the structure of the chain multiyne compound is adjustable. The chain multiyne compound can also be used to synthesize the fused-ring metallacyclic compound efficiently. The preparation method of the chain multiyne compound disclosed in the present invention is simple, which can be used to prepare the chain multiyne compound rapidly and efficiently. 5. The preparation method of the chain multiyne compound according to claim 4 , characterized in that the preparation method 1 also comprises using a deprotection agent to take off the protection group Y from the obtained chain multiyne compound with a protection group Y of Formula IV; wherein the deprotection agent is at least any one of KCO claim 4 , NaCO claim 4 , CsCO claim 4 , KF claim 4 , (n-Bu)NF (tetrabutylammonium fluoride) claim 4 , (Et)NF (tetraethylammonium fluoride) claim 4 , (Me)NF (tetramethylammonium fluoride) and (n-Pr)NF (tetrapropylammonium fluoride).6. The preparation method of the chain multiyne compound according to claim 5 , characterized in that before the deprotection agent takes off the protection group Y from the obtained chain multiyne compound with a protection group Y of Formula IV claim 5 , quenching and purifying processes are performed on the reaction mixture of step a.7. The preparation method of the chain multiyne compound according to claim 5 , characterized in that after the ...

NOVEL PROCESS FOR THE PREPARATION OF CANAGLIFLOZIN

The present invention provides a novel process for the preparation of Canagliflozin (I) and its hydrates thereof by employing novel intermediates. The present invention is also provides commercially and industrial applicable process. 1. A process for the preparation of canagliflozin (I) comprising the steps of:a. reacting (5-bromo-2-methylphenyl) [5-(4-fluorophenyl) thiophen-2-yl] methanone (IV) with a tri alkyl orthoformate or tri alkyl orthoaceatate (XV), optionally in the presence of acid, to produce 2-[(5-bromo-2-methylphenyl)(dimethoxy)methyl]-5-(4-fluorophenyl)thiophene (XVI);b. the product of step a) is condensed with 2,3,5,6 tetrakis-O-trimethylsilyl-D-glucanolactone (VI) in the presence of a Grignard reagent or an organo lithium reagent to produce [5-(4-fluorophenyl)-thiophen-2-yl]-[2-methyl-5-(3, 4, 5-trihydroxy-6-hydroxymethyl-2-methoxy-tetrahydro-pyran-2-yl)-phenyl]-methanone (XVII);c. the product of step b) is deprotected in the presence of acid and solvent to produce [5-(4-fluorophenyl)-thiophen-2-yl]-[2-methyl-5-(3,4,5-trihydroxy-6-hydroxymethyl-2-methoxy-tetrahydro-pyran-2-yl)-phenyl]-methanone (VIII); andd. the product of step c) is reduced with trialkyl silane and a Lewis acid to produce canagliflozin (I).2. The process according to claim 1 , wherein in step-a) the alkyl orthoformate is selected form trimethyl orthoformate and triethyl orthoformate claim 1 , and the acid is selected from hydrochloric acid claim 1 , sulfuric acid claim 1 , methane sulfonic acid claim 1 , and p-toluene sulfonic acid.3. The process according to claim 1 , wherein in step-b) the Grignard reagent is magnesium halide where the halide is selected from chloride claim 1 , fluoride claim 1 , bromide claim 1 , and iodide.4. The process according to claim 1 , wherein in step-b) the organo lithium reagent is selected from methyl lithium claim 1 , sec-butyl lithium claim 1 , iso propyl lithium claim 1 , n-butyl lithium claim 1 , t-butyl lithium and phenyl lithium.5. The process ...

Compounds containing a pentalene unit and process for their preparation

Compound containing a pentalene unit having general formula (I) wherein R 1 and R 2 , equal to or different from each other, are selected from: linear or branched C 1 -C 20 , preferably C 2 -C 12 , alkyl groups, saturated or unsaturated, optionally containing heteroatoms, cycloalkyl groups optionally substituted, linear or branched C 1 -C 20 , preferably C 2 -C 12 , alkoxyl groups, saturated or unsaturated, optionally substituted; or the groups R 1 and R 2 can be optionally bound to each other so as to form, together with the carbon atoms to which they are bound, a cycle or a polycyclic system containing from 3 to 14 carbon atoms, preferably from 4 to 6 carbon atoms, saturated, unsaturated, or aromatic, optionally containing one or more heteroatoms such as, for example, oxygen, sulfur, nitrogen, silicon, phosphorous, selenium; R 3 is selected from aryl groups optionally substituted, heteroaryl groups optionally substituted; n is 0 or 1; with the proviso that: when n is 0, X represents a covalent bond and Y represents a sulfur atom (S); when n is 1, X is equal to Y, and represents a CH group, or a nitrogen atom (N). Said compound containing a pentalene unit, as such or after suit able functionalization and polymerization, can be advantageously used in the construction of photovoltaic devices (or solar devices) such as, for example, photovoltaic cells (or solar cells), photovoltaic modules (or solar modules), on both rigid and flexible supports. Said compound containing a pentalene unit can also be advantageously used as a constitutive unit of luminescent solar concentrators (LSCs). Furthermore, said compound containing a pentalene unit can be advantageously used as precursor of monomeric units in the preparation of semiconductor polymers.

PROCESS FOR PREPARATION OF CANAGLIFLOZIN

The present invention relates to a process for the preparation of canagliflozin and intermediates thereof. 2. The process as claimed in claim 1 , wherein in step (a) the reducing agent is selected from the group consisting of diborane claim 1 , diazene claim 1 , sodium borohydride claim 1 , potassium borohydride claim 1 , lithium aluminium hydride and diisobutyl aluminium hydride and aluminum hydride.3. The process as claimed in claim 1 , wherein in step (a) the compound of formula II is reduced to the compound of formula in the absence of a Lewis acid.4. The process as claimed in claim 1 , wherein in step (b) the coupling reaction is carried out in presence of a base selected from the group consisting of -butyl lithium claim 1 , sec-butyl lithium claim 1 , sodium hydride claim 1 , potassium hydride and a isopropylmagnesium chloride.lithium chloride complex.5. The process as claimed in . wherein in step (c) the compound of formula V is converted to the compound of formula VI in the presence of an acid.6. The process as claimed in claim 1 , wherein in step (d) the compound of formula VI is converted to the compound of formula I by treating the compound of formula VI with a reducing agent.7. The process as claimed in claim 6 , wherein the reducing agent is triethyl silane.813.-. (canceled) This application claims the benefit of Indian Provisional Application 1776/MUM/2014 filed on May 27, 2014, entitled “PROCESS FOR PREPARATION OF CANAGLIFLOZIN”, the contents of which are incorporated herein by reference.The present invention relates to process of preparation of canagliflozin.Canagliflozin which is chemically known as 1(S)-1,5-anhydro-1-[3[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol, is represented by a compound of formula I,Canagliflozin, is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.In one embodiment, the present invention ...

ELECTROCHROMIC COMPOSITION AND ELECTROCHROMIC ELEMENT

An electrochromic composition has an anodic electrochromic compound and a cathodic electrochromic compound, in which the anodic electrochromic compound is represented by General Formula [1] 2. The electrochromic composition according to claim 1 , wherein at least either one of Aor Ais an alkoxy group in which the number of carbon atoms is 1 or more and 20 or less.3. The electrochromic composition according to claim 1 , wherein at least either one of Aor Ais an alkoxy group in which the number of carbon atoms is 1 or more and 20 or less.4. The electrochromic composition according to claim 1 , wherein the alkoxy group represented by at least either one of Aor Ais a methoxy group or an isopropoxy group claim 1 , and the alkoxy group represented by at least either one of Aor Ais a methoxy group or an isopropoxy group.5. The electrochromic composition according to claim 1 , wherein Rand Rabove are electron withdrawing substituents.6. The electrochromic composition according to claim 5 , wherein Rand Rabove each are any one of a tert-butyl group claim 5 , a trifluoromethyl group claim 5 , a methoxy group claim 5 , a benzyloxy group claim 5 , a methyl ester group claim 5 , or a cyano group.7. The electrochromic composition according to claim 1 , wherein a weight ratio of the electrochromic compound represented by General Formula [1] is 10% by mol or more and 90% by mol or less when a total of the electrochromic compound represented by General Formula [1] and the electrochromic compound represented by General Formula [2] is 100% by mol.8. The electrochromic composition according to comprising a third electrochromic compound which is different from the electrochromic compound represented by General Formula [1] and the electrochromic compound represented by General Formula [2].9. The electrochromic composition according to further comprising a solvent and an electrolyte.10. The electrochromic composition according to claim 9 , wherein a concentration of the electrolyte is ...

STRUCTURE, SYNTHESIS, AND APPLICATIONS FOR POLY(PHENYLENE ETHYNYLENES) (PPEs)

The present disclosure provides novel poly(phenylene ethynylene) (PPE) compounds, methods for synthesizing these compounds, and materials and substances incorporating these compounds. The various PPEs show antibacterial, antiviral and antifungal activity. 2. The material of claim 1 , wherein the biological species comprises a protein claim 1 , cell claim 1 , bacteria claim 1 , virus claim 1 , or combination thereof.3. The material of claim 1 , wherein claim 1 , when the SRM is in an active form claim 1 , the poly(phenylene ethynylene) exhibits at least one of biocidal activity claim 1 , antiviral activity claim 1 , antibacterial activity claim 1 , and antifungal activity.4. The material of claim 1 , wherein the material comprises a film comprising the poly(phenylene ethynylene) and the SRM.5. The material of claim 4 , wherein when the SRM is in the inactive form the film contracts and becomes hydrophobic thereby attracting the biological species claim 4 , and when the SRM is in the active form the film expands and releases or does not attract the biological species.6. The material of claim 4 , wherein the film is a self-cleaning reusable film.7. The material of claim 4 , wherein changing the SRM from the inactive form to the active form releases biological species from the film thereby self-cleaning the film and preparing the film for reuse.8. The material of claim 1 , wherein antimicrobial activity of the poly(phenylene ethynylene) is masked when the SRM is in the inactive form claim 1 , and the poly(phenylene ethynylene) has antimicrobial activity when the SRM is in the active form.9. The material of claim 1 , wherein the SRM changes between the active and inactive form in response to temperature.10. The material of claim 9 , wherein below a lower critical solution temperature (LCST) the material releases or does not attract the biological species claim 9 , wherein above the LCST the material attracts the biological species.11. The material of claim 10 , wherein a ...

Compounds having multimodal activity against pain

wherein the meanings for the various substituents are as disclosed in the description, having dual pharmacological activity towards both the α2δ subunit, in particular the α2δ-1 subunit, of the voltage-gated calcium channel and the NET receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM

Provided is a fluorine-containing ether compound that can be suitably used as a material for a lubricant for a magnetic recording medium, capable of forming a lubricant layer having excellent chemical substance resistance and wear resistance even when the thickness is small. A fluorine-containing ether compound represented by the following formula (1): 1. A fluorine-containing ether compound represented by the following formula (1) ,{'br': None, 'sup': 1', '2', '3', '4', '5, 'sub': 2', '2, 'R—R—CH—R—CH—R—R\u2003\u2003(1)'}{'sup': 3', '2', '4', '1', '5', '2', '4', '1', '5, 'wherein in the formula (1), Ris a perfluoropolyether chain; Rand Rare divalent linkage groups having a polar group and may be the same or different; Rand Rare terminal groups bonded to Ror Rand may be the same or different; and at least one of Rand Ris an organic group having 1 to 8 carbon atoms wherein one or more hydrogen atoms of the organic group is substituted with a cyano group.'}2. The fluorine-containing ether compound according to claim 1 , wherein the organic group is a phenyl group or an alkyl group having 1 to 5 carbon atoms.3. The fluorine-containing ether compound according to claim 1 , wherein the polar group is a hydroxy group.4. The fluorine-containing ether compound according to claim 1 , wherein Rand Rin the formula (1) are represented by the following formula (2-1) claim 1 ,{'br': None, 'sub': 2', '2', 'a, '—(X—CHCH(OH)CH)—X—\u2003\u2003(2-1)'}{'sub': '2', 'wherein in the formula (2-1), a represents an integer of 1 to 3, X represents an oxygen atom or CH, and two X may be the same or different.'}5. The fluorine-containing ether compound according to claim 4 , wherein a in the formula (2-1) is 1 or 2 claim 4 , and each X is an oxygen atom.6. The fluorinated ether compound according to claim 1 , wherein Rin the formula (1) is any one of the following formulas (3) to (5) claim 1 ,{'br': None, 'sub': 2', '2', '2', 'c', '2', 'a', '2, '—CFO—(CFCFO)—(CFO)—CF—\u2003\u2003(3)'} {'br': ...

METHOD FOR THE PREPARATION OF A PARTIALLY HYDROGENATED POLYACENE AND AN INTERMEDIATE THEREOF

The present invention relates to a process for preparing a partially hydrogenated polyacene, and a novel intermediate used in such process; also the present invention relates to a process for preparing the corresponding conjugated polyacenes. 2. The method according to wherein each of R claim 1 , R claim 1 , Rand R claim 1 , which may be the same or different claim 1 , is independently selected from the group consisting of: hydrogen claim 1 , halogen claim 1 , straight chain or branched (C-C)alkyl claim 1 , (C-C)haloalkyl claim 1 , (C-C)alkyloxy claim 1 , (C-C)thioalkyl claim 1 , (C-C)alkylcarbonyl claim 1 , (C-C)alkylcarbonyloxy claim 1 , (C-C)alkyloxycarbonyl claim 1 , a radical of formula Si((C-C)alkyl) claim 1 , (C-C)alkylcarbonylamino claim 1 , (C-C)alkylaminocarbonyl claim 1 , an aldehyde group claim 1 , cyano claim 1 , nitro claim 1 , a (C-C)aryl optionally substituted at one or more positions with a radical selected from the group consisting of halogen claim 1 , (C-C)alkyl claim 1 , (C-C)haloalkyl claim 1 , (C-C)alkyloxy claim 1 , (C-C)thioalkyl claim 1 , (C-C)alkylcarbonyl claim 1 , (C-C)alkylcarbonyloxy claim 1 , (C-C)alkyloxycarbonyl claim 1 , a radical of formula Si((C-C)alkyl) claim 1 , (C-C)alkylcarbonylamino claim 1 , (C-C)alkylaminocarbonyl claim 1 , cyano claim 1 , nitro claim 1 , and an aldehyde group and a (C-C)heteroaryl optionally substituted at one or more positions with a radical selected from the group consisting of halogen claim 1 , (C-C)alkyl claim 1 , (C-C)haloalkyl claim 1 , (C-C)alkyloxy claim 1 , (C-C)thioalkyl claim 1 , (C-C)alkylcarbonyl claim 1 , (C-C)alkylcarbonyloxy claim 1 , (C-C)alkyloxycarbonyl claim 1 , a radical of formula Si((C-C)alkyl) claim 1 , (C-C)alkylcarbonylamino claim 1 , (C-C)alkylaminocarbonyl claim 1 , cyano claim 1 , nitro claim 1 , and an aldehyde group; or claim 1 , alternatively claim 1 ,{'sub': 11', '12', '12', '13', '13', '14', '2', '10', '10', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6', '2', '6', '2', ...

NOVEL ORGANOLEPTIC COMPOUNDS AND THEIR USE IN FLAVOR AND FRAGRANCE COMPOSITIONS

The present invention is directed to novel organoleptic compounds, a process of augmenting, enhancing or imparting taste to a material selected from the group consisting of a foodstuff, a chewing gum, a dental product, an oral hygiene product and a medicinal product comprising the step of incorporating an olfactory acceptable amount of such novel organoleptic compounds, and a process of improving, enhancing or modifying a fragrance composition through the addition of an olfactory acceptable amount of such novel organoleptic compounds. 6. The compound of selected from the group consisting of:3-mercapto-3,7-dimethyl-oct-6-en-1-ol;3-mercapto-3,7-dimethyl-oct-6-enal;S-[1-(2-hydroxy-ethyl)-1,5-dimethyl-hex-4-enyl]-thioacetate; and3-acetylsulfanyl-3,7-dimethyl-oct-6-enyl acetate.7. A flavor composition comprising an olfactory acceptable amount of the compound of any of the preceding claims.8. The flavor composition of further comprising a material selected from the group consisting of a foodstuff claim 7 , a chewing gum claim 7 , a dental product claim 7 , an oral hygiene product and a medicinal product.9. The flavor composition of claim 7 , wherein the olfactory acceptable amount is from about 1 part per billion to about 1000 parts per million by weight.10. The flavor composition of claim 7 , wherein the olfactory acceptable amount is from about 10 parts per billion to about 100 parts per million by weight.11. The flavor composition of claim 7 , wherein the olfactory acceptable amount is from about 100 parts per billion to about 10 parts per million by weight.12. A method of improving claim 7 , enhancing or modifying a flavor composition through the addition of an olfactory acceptable amount of the compound of any of the preceding claims.13. A fragrance composition comprising an olfactory acceptable amount of the compound of any of the preceding claims.14. The fragrance composition of further comprising a material selected from the group consisting of a polymer and a non ...

CLEAVABLE SURFACTANTS

The invention provides surfactant compounds of formulas I-IX, which can be used in methods for aiding the solubilization, digestion, preparation, analysis, and/or characterization of biological material, for example, proteins or cell membranes. The compounds can also aid in the recovery of peptides generated during protein digestion, particularly for in-gel digestion protocol. Additionally, the compounds can improve enzymatic protein deglycosylation without interfering with downstream sample preparation steps and mass spectrometric analysis. The compounds can be specifically useful as digestion aids that can be decomposed by an acid, by heat, or a combination thereof. Decomposition of the surfactants allows for facile separation from isolated samples, and/or allows for analysis of the sample without interfering with the sensitivity of various analytical techniques. 110-. (canceled)12. The method of wherein the biomaterial is in a gel or is bound to a solid support.13. The method of wherein the biomaterial is in an aqueous solution.14. The method wherein the digestion reagent comprises one or more of a protease claim 11 , CNBr claim 11 , or hydroxylamine.15. The method of wherein the protease is a serine protease.16. The method of wherein the serine protease is trypsin or chymotrypsin.17. The method of further comprising decomposing the surfactant compound after protein digestion claim 11 , wherein the degrading optionally comprises contacting the surfactant compound with an acidic solution claim 11 , heating the surfactant compound claim 11 , or a combination thereof.18. The method of wherein the surfactant compound self-hydrolyses in solution after protein digestion.19. The method of further comprising isolating the one or more digested proteins.20. The method of further comprising analyzing the digested proteins claim 11 , wherein the digested proteins are analyzed by mass spectrometry claim 11 , liquid chromatography claim 11 , gel electrophoresis claim 11 , or a ...

FLUOROALKYLATING AGENT

Problem to be Solved 2. The agent according to claim 1 , wherein{'sup': '1', 'Ris a C1 to C4 perfluoroalkyl group;'}{'sup': 2', '3, 'Rand Rare each independently a C1 to C4 alkyl group or a phenyl group;'}{'sup': 1', '2', '3', '4, 'Y, Y, Yand Yare each independently'}a hydrogen atom, a halogen atom, a nitro group, a cyano group,a C1 to C4 alkyl group or a C1 to C4 haloalkyl group; and{'sup': −', '−', '−', '−, 'X is Cl, Br, I,'}{'sub': '4', 'sup': '−', 'BF,'}{'sub': 3', '3, 'sup': '−', 'CFSO,'}{'sub': 3', '3', '3', '2', '5', '3, 'sup': −', '−', '−, 'HOSO, CHOSO or CHOSO.'}3. The agent according to claim 1 , wherein{'sup': '1', 'Ris a trifluoromethyl group or a pentafluoroethyl group;'}{'sup': 2', '3, 'Rand Rare each independently a methyl group, an ethyl group or a phenyl group;'}{'sup': 1', '2', '3', '4, 'Y, Y, Yand Yare each independently a hydrogen atom, a chlorine atom or a nitro group; and'}{'sup': −', '−', '−', '−, 'X is Cl, Br, I,'}{'sub': '4', 'sup': '−', 'BF,'}{'sub': 3', '3, 'sup': '−', 'CFSO,'}{'sub': 3', '3', '3', '2', '5', '3, 'sup': −', '−', '−, 'HOSO, CHOSO or CHOSO.'}4. The agent according to claim 1 , wherein{'sup': '1', 'Ris a trifluoromethyl group;'}{'sup': 2', '3, 'Rand Rare each a methyl group;'}{'sup': 1', '2', '3', '4, 'Y, Y, Yand Yare each a hydrogen atom; and'}{'sup': −', '−, 'sub': 3', '3, 'X is CHOSO.'}6. The method according to claim 5 , wherein{'sup': '1', 'Ris a C1 to C4 perfluoroalkyl group;'}{'sup': 2', '3, 'Rand Rare each independently a C1 to C4 alkyl group or a phenyl group;'}{'sup': 1', '2', '3', '4, 'Y, Y, Yand Yare each independently'}a hydrogen atom, a halogen atom, a nitro group, a cyano group,a C1 to C4 alkyl group or a C1 to C4 haloalkyl group; and{'sup': −', '−', '−', '−, 'X is Cl, Br, I,'}{'sub': '4', 'sup': '−', 'BF,'}{'sub': 3', '3, 'sup': '−', 'CFSO,'}{'sub': 3', '3', '3', '2', '5', '3, 'sup': −', '−', '−, 'HOSO, CHOSO or CHOSO.'}7. The method according to claim 5 , wherein{'sup': '1', 'Ris a trifluoromethyl group or a ...

Conducting Polymers and Uses Thereof

The present invention generally relates to the field of conducting polymers. More specifically, the present invention relates to polymerisable monomers comprising a probe capable of binding one or more nucleic acids or comprising a nucleic acid or an analogue thereof, conducting polymers comprising monomer units of such monomers, and methods of making such polymers. The present invention also relates to sensors comprising the polymers, sensor systems comprising the sensors, methods of making the sensors, and methods for determining the presence or absence or amount of targets employing the sensors. The present invention also relates to methods, systems and apparatuses for amplifying nucleic acids employing the conducting polymers. 3. The polymerisable monomer of any one if the preceding claims , wherein p is 2.4. The polymerisable monomer of claim 3 , wherein each D is identical.6. The polymerisable monomer of any one of the preceding claims claim 3 , wherein{'sup': 1', '2', '3', '4', '5', '5', '5', '5', '5', '5', '5', '5', '5', '5', '5', '5', '5', '6, 'R, R, R, and Rare each independently selected from the group consisting of hydrogen, halo, nitro, nitrile, —C(O)R, —OR, —C(O)OR, —OC(O)R, —NRR, —C(O)NRR, —NRC(O)R, —NRC(O)NRR, and —R; or'}{'sup': 1', '2', '3', '4, 'Rand Rand/or Rand Rtogether with the atoms to which they are attached form a five or six membered heterocyclic or carbocyclic ring;'}{'sup': '5', 'Rat each instance is independently selected from the group consisting of hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, and heteroaryl; and'}{'sup': 6', '5', '5', '5', '5', '5', '5', '5', '5', '5', '5', '5', '5', '5, 'Rat each instance is independently selected from the group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heterocyclyl, and heteroaryl, each of which is optionally substituted with one or more substituents independently selected from halo, nitro, nitrile, —C(O)R, —OR, —C(O)OR, —OC(O)R, —NRR, —C(O) ...

PHOTOISOMERIC COMPOUNDS AND DEVICE COMPRISING THE SAME

Disclosed are a series of photoisomeric compounds, preparation method therefor and device comprising the compounds, wherein a photoisomeric compound-graphene molecular junction device is formed by linking the photoisomeric compound to a gap of two-dimensional monolayer graphene having a nano-gap array via an amide covalent bond. When a single photoisomeric compound is bridged to the gap of the two-dimensional monolayer graphene having a nano-gap array, the devices have a reversible light-controlled switching function and a reversible electrically-controlled switching function. A molecular switch device prepared by the method can achieve a high reversibility and a good reproducibility. The number of light-controlled switching cycles can exceed 10, and the number of electrically-controlled switching cycles can reach about 10or greater. Moreover, the above-mentioned reversible molecular switch device remains stable within a period of more than one year. In addition, flexible non-losable organic memory transistor devices and light-responsive organic transistor devices can be constructed using the above-mentioned series of photoisomeric compounds. 118-. (canceled)21. A reversible molecular switch device or a transistor device , wherein:{'claim-ref': {'@idref': 'CLM-00019', 'claim 19'}, '(1) the reversible molecular switch device is a reversible light-controlled molecular switch device comprising the diarylethene-graphene molecular junction device of , wherein the reversible light-controlled molecular switch device exhibits a high conductive state under ultraviolet light; and the reversible light-controlled molecular switch device exhibits a low conductive state under visible light;'}{'claim-ref': {'@idref': 'CLM-00019', 'claim 19'}, '(2) the reversible molecular switch device is a reversible electrically-controlled molecular switch device comprising the diarylethene-graphene molecular junction device of and a voltage generating means connected to the molecular junction ...

ORGANIC COMPOUND AND ELECTROCHROMIC DEVICE USING THE SAME

The present invention provides an organic compound represented by the following general formula [1], the organic compound having high solubility in a polar solvent used in an EC device, high transparency in the bleached state and high stability against repetition of an oxidation-reduction reaction. 2. The organic compound according to claim 1 , wherein the Ais the same substituent as the A claim 1 , and the Ais the same substituent as the A.3. The organic compound according to claim 1 , wherein at least one of the Ato the Ais an alkoxy group having 1 or more and 20 or less carbon atoms.4. The organic compound according to claim 3 , wherein the alkoxy group is a methoxy group or an isopropoxy group.5. The organic compound according to claim 1 , wherein the X is an integer of 1 or more and 5 or less.6. An electrochromic device comprising:a pair of electrodes; andan electrochromic layer arranged between the pair of electrodes,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'wherein the electrochromic layer contains an electrochromic compound and an electrolyte, and the electrochromic compound is an organic compound according to .'}7. The electrochromic device according to claim 6 , wherein the electrochromic layer is a layer comprising a liquid material containing the electrochromic compound and the electrolyte.8. The electrochromic device according to claim 6 , wherein the electrochromic layer further contains a second electrochromic compound which is a material other than the organic compound.9. The electrochromic device according to claim 8 , wherein the second electrochromic compound is a compound having low visible light transmittance in the reduced state.10. An optical filter comprising an electrochromic device according to and an active element connected to the electrochromic device.11. A lens unit comprising a plurality of lenses and an optical filter according to .12. An imaging device comprising an optical filter according to and a photodetection element ...

PHOTOISOMERIC COMPOUNDS AND DEVICE COMPRISING THE SAME

Disclosed are a series of photoisomeric compounds, preparation method therefor and device comprising the compounds. A photoisomeric compound-grephene molecular junction device is formed by linking the photoisomeric compound to a gap of two-dimensional monolayer graphene having a nano-gap array via an amide covalent bond. When a single photoisomeric compound is bridged to the gap of the two-dimensional monolayer graphene having a nano-gap array, the devices have a reversible light-controlled switching function and a reversible electrically-controlled switching function. A molecular switch device prepared by the method can achieve high reversibility and good reproducibility. The number of light-controlled switching cycles can exceed 10, and the number of electrically-controlled switching cycles can reach about 10or greater. The reversible molecular switch device remains stable within a period of more than one year. Flexible non-losable organic memory transistor devices and light-responsive organic transistor devices can be constructed using the series of photoisomeric compounds. 2. A diarylethene-graphene molecular junction device claim 1 , wherein the molecular junction device comprises any one of the diarylethene compound of claim 1 , linked to a gap of a two-dimensional monolayer graphene having a nanogap array via an amide covalent bond.3. A reversible molecular switch device or a transistor device claim 1 , wherein:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, '(1) the reversible molecular switch device is a reversible light-controlled molecular switch device comprising the diarylethene-graphene molecular junction device of , wherein the reversible light-controlled molecular switch device exhibits a high conductive state under ultraviolet light; and the reversible light-controlled molecular switch device exhibits a low conductive state under visible light;'}{'sub': '7', 'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'claim-text': (a) a voltage of 0.2 V to 1 ...

FLUOROALKYLATING AGENT

Problem to be Solved 14.-. (canceled)6. The method according to claim 5 , wherein{'sup': '1', 'Ris a C1 to C4 perfluoroalkyl group;'}{'sup': 2', '3, 'Rand Rare each independently a C1 to C4 alkyl group or a phenyl group;'}{'sup': 1', '2', '3', '4, 'Y, Y, Yand Yare each independently'}a hydrogen atom, a halogen atom, a nitro group, a cyano group,a C1 to C4 alkyl group or a C1 to C4 haloalkyl group; and{'sup': −', '−', '−', '−, 'X is Cl, Br, I,'}{'sub': '4', 'sup': '−', 'BF,'}{'sub': 3', '3, 'sup': '−', 'CFSO,'}{'sub': 3', '3', '3', '2', '5', '3, 'sup': −', '−', '−, 'HOSO, CHOSO or CHOSO.'}7. The method according to claim 5 , wherein{'sup': '1', 'Ris a trifluoromethyl group or a pentafluoroethyl group;'}{'sup': 2', '3, 'Rand Rare each independently a methyl group, an ethyl group or a phenyl group;'}{'sup': 1', '2', '3', '4, 'Y, Y, Yand Yare each independently a hydrogen atom, a chlorine atom or a nitro group; and'}{'sup': −', '−', '−', '−, 'X is Cl, Br, I,'}{'sub': '4', 'sup': '−', 'BF,'}{'sub': 3', '3, 'sup': '−', 'CFSO,'}{'sub': 3', '3', '3', '2', '5', '3, 'sup': −', '−', '−, 'HOSO, CHOSO or CHOSO.'}8. The method according to claim 5 , wherein{'sup': '1', 'Ris a trifluoromethyl group;'}{'sup': 2', '3, 'Rand Rare each a methyl group;'}{'sup': 1', '2', '3', '4, 'Y, Y, Yand Yare each a hydrogen atom; and'}{'sup': −', '−, 'sub': 3', '3, 'X is CHOSO.'}9. The method according to claim 5 , wherein the reaction is carried out in the presence of a zeolite.10. The method according to claim 9 , wherein the zeolite is a molecular sieve 3A claim 9 , a molecular sieve 4A or a molecular sieve 5A.12. The method according to claim 11 , wherein{'sup': '1', 'Ris a C1 to C4 perfluoroalkyl group;'}{'sup': 2', '3, 'Rand Rare each independently a C1 to C4 alkyl group or a phenyl group;'}{'sup': 1', '2', '3', '4, 'Y, Y, Yand Yare each independently'}a hydrogen atom, a halogen atom, a nitro group, a cyano group,a C1 to C4 alkyl group or a C1 to C4 haloalkyl group; and{'sup': −', '−', '−', ...

PROCESS FOR THE PREPARATION OF CANAGLIFLOZIN

A process for the preparation of canagliflozin. The process may be effectively implemented on an industrial scale. Several compounds useful as intermediates for the synthesis of canagliflozin (Formula 4, Formula 4a, Formula 4b and Formula 5) are also disclosed. The process involves the reduction of the compound of formula 3 in the presence of a metal hydride and an organic solvent to obtain the compound of formula 4, converting this into a compound of formula 5 which in turn is converted into canagliflozin. 2. The process according to claim 1 , wherein the metal hydride is selected from the group consisting of sodium borohydride claim 1 , diisobutylaluminum hydride claim 1 , and lithium aluminum hydride.3. The process according to claim 1 , wherein the organic solvent is selected from the group consisting of methanol claim 1 , ethanol claim 1 , isopropanol claim 1 , and mixtures thereof.4. The process according to claim 1 , wherein the converting of formula 5 to canagliflozin is carried out using a reducing agent in the presence of a Lewis acid and an organic solvent.5. The process according to claim 4 , wherein the reducing agent is triethylsilane.6. The process according to claim 4 , wherein the Lewis acid is aluminum chloride or boron trifluoride-ethyl ether complex.7. The process according to claim 4 , wherein the organic solvent is selected from the group consisting of acetone claim 4 , dichloromethane claim 4 , ethyl acetate claim 4 , methyl tert-butyl ether claim 4 , acetonitrile claim 4 , and mixtures thereof.8. The process according to claim 1 , further comprising purifying the canagliflozin after converting formula 5 to canagliflozin.9. The process according to claim 8 , wherein the purifying is carried out by distillation or by adding an anti-solvent.10. The process according to claim 9 , wherein the distillation is carried out by adding a polar solvent.11. The process according to claim 10 , wherein the polar solvent is a ketone claim 10 , an alcohol ...

CLEAVABLE SURFACTANTS

The invention provides surfactant compounds of formulas I-IX, which can be used in methods for aiding the solubilization, digestion, preparation, analysis, and/or characterization of biological material, for example, proteins or cell membranes. The compounds can also aid in the recovery of peptides generated during protein digestion, particularly for in-gel digestion protocol. Additionally, the compounds can improve enzymatic protein deglycosylation without interfering with downstream sample preparation steps and mass spectrometric analysis. The compounds can be specifically useful as digestion aids that can be decomposed by an acid, by heat, or a combination thereof. Decomposition of the surfactants allows for facile separation from isolated samples, and/or allows for analysis of the sample without interfering with the sensitivity of various analytical techniques. 131-. (canceled)33. The compound of claim 32 , wherein Q is (C-C)alkyl.34. The compound of claim 33 , wherein Q is optionally substituted with hydroxy.35. The compound of claim 32 , wherein X is NH claim 32 , and Z is O.36. The compound of claim 32 , wherein M is H or Na.37. The compound of claim 32 , wherein L is a direct bond.38. The compound of claim 32 , wherein Ris (C-C)alkyl.39. The compound of claim 32 , wherein Ris (C-C)alkyl.40. The compound of claim 32 , wherein Rand Rare each (C-C)alkyl.41. The compound of claim 32 , wherein Rand Rare each methyl.42. The compound of claim 32 , wherein:{'sub': 2', '3, 'Q is (C-C)alkyl, which is unsubstituted or substituted with hydroxy;'}X is NH, and Z is O;M is H or Na;L is a direct bond;{'sup': '1', 'sub': 4', '20, 'Ris unsubstituted (C-C)alkyl; and'}{'sup': 2', '3, 'sub': 1', '6, 'Rand Rare each unsubstituted (C-C)alkyl.'}43. The compound of claim 42 , wherein:{'sup': '1', 'sub': 10', '14, 'Ris unsubstituted (C-C)alkyl; and'}{'sup': 2', '3, 'Rand Rare each methyl.'}461. A composition comprising a gel and a compound of claim .47. The composition of claim 46 , ...

IRON(II) CATALYSTS CONTAINING TRIDENTATE PNP LIGANDS, THEIR SYNTHESIS, AND USE THEREOF

The application describes catalytic materials for hydrogenation or asymmetric hydrogenation. In particular, the application describes iron(ll) complexes containing tridentate diphosphine PNP ligands useful for catalytic hydrogenation. 8. The complex of any one of - , wherein each Ris independently C-Calkyl or C-Ccycloalkyl; or , alternatively C-Calkyl or C-Ccycloalkyl; and , each Ris independently aryl , or heteroaryl.9. The complex of claim 8 , wherein each Ris independently isopropyl or cyclohexyl; and claim 8 , each Ris phenyl.10. The complex of any one of - claim 8 , wherein Rand Rare each independently H claim 8 , C-Calkyl claim 8 , aryl claim 8 , or heteroaryl; or claim 8 , alternatively H claim 8 , C-Calkyl claim 8 , aryl claim 8 , or heteroaryl; and claim 8 , each R claim 8 , R claim 8 , R claim 8 , Rand Ris H.11. The complex of claim 10 , wherein Rand Rare each independently H claim 10 , methyl claim 10 , isopropyl claim 10 , phenyl claim 10 , or benzyl.12. The complex of or claim 10 , wherein Ris C-Calkyl claim 10 , C-Calkenyl claim 10 , C-Ccycloalkyl claim 10 , aryl claim 10 , or heteroaryl; or claim 10 , alternatively claim 10 , Ris C-Calkyl claim 10 , C-Calkenyl claim 10 , C-Ccycloalkyl claim 10 , aryl claim 10 , or heteroaryl.13. The complex of claim 12 , wherein Ris methyl claim 12 , ethyl claim 12 , t-butyl claim 12 , or t-amyl.14. The complex of or claim 12 , wherein Z is an alkali metal cation.15. The complex of claim 14 , wherein Z is K claim 14 , Na claim 14 , or Li.16. The complex of or claim 14 , wherein Y is a conjugate base of a strong acid.17. The complex of claim 16 , wherein Y is a halide claim 16 , BF claim 16 , PF claim 16 , SbF claim 16 , NO claim 16 , ClO claim 16 , CFCOO claim 16 , RSO claim 16 , CFSO claim 16 , CHSO claim 16 , p-CHCHSO claim 16 , phosphates claim 16 , TRISPHAT(Δ- or Λ-P(OCClO)) claim 16 , carboranes claim 16 , B(R) or Al(R) claim 16 , each of which may be substituted claim 16 , wherein each Ris independently an ...

AROMATIC SURFACTANTS

Disclosed are compounds of the Formula 1 wherein A is an aromatic moiety; H is a hydrophobic group comprising a main alkyl chain having from about 3 to about 26 carbon atoms and comprising a Cor greater alkyl chain branched from the main alkyl chain; and K is a hydrophilic group. 2. The compound according to claim 1 , wherein the branched alkyl chain is ethyl claim 1 , or propyl.3. (canceled)4. The compound according to claim 1 , wherein A is a functionalized or non-functionalized furan moiety.5. (canceled)6. The compound according to claim 1 , wherein A is a disubstituted furan ring.7. The compound according to claim 1 , wherein A is thiophene claim 1 , pyrrole claim 1 , imidazole claim 1 , or pyridine.14. (canceled)15. (canceled)18. (canceled)19. The compound according to claim 17 , wherein L comprises two ether groups directly connected to the alpha-carbons adjacent the aromatic moieties and the two ether groups are connected via an alkyl chain having from about 1 to about 20 carbons.22. (canceled)27. (canceled)28. (canceled)29. (canceled)30. (canceled) This application claims priority to U.S. Provisional Application Nos. 62/252,200 filed on Nov. 6, 2015 entitled Methods of Forming Aromatic and Linear Chain Containing Compounds; and 62/403,305 filed on Oct. 3, 2016 entitled Aromatic Surfactants; the entire disclosures of which are incorporated herein by reference thereto.This invention was made with government support under DE-SC0001004 awarded by the Department of Energy. The government has certain rights in the invention.Disclosed are compounds of the Formula 1wherein A is an aromatic moiety; H is a hydrophobic group comprising a main alkyl chain having from about 3 to about 26 carbon atoms and comprising a Cor greater alkyl chain branched from the main alkyl chain; and K is a hydrophilic group.Also disclosed are compounds of formula 3wherein K is a hydrophilic group, A is an aromatic moiety and R is a hydrophobic group comprising a main alkyl chain having from ...

LUMINESCENT NANOCRYSTAL COMPLEX

“Object” A problem to be solved by the present invention is to provide a luminescent nanocrystal complex that tends to disperse orderly in a polymer matrix and is superior in dispersibility in structurally mesogenic crosslinkable polymer matrices. “Solution” The present invention is a luminescent nanocrystal complex that contains luminescent nanocrystals and a surface-modifying compound that modifies the surface of the luminescent nanocrystals. The surface-modifying compound has a mesogenic backbone and a group that binds to the surface of the luminescent nanocrystals. 1. A luminescent nanocrystal complex comprising luminescent nanocrystals and a surface-modifying compound modifying a surface of the luminescent nanocrystals , whereinthe surface-modifying compound has a mesogenic group and at least one group that binds to the surface of the luminescent nanocrystals.2. The luminescent nanocrystal complex according to claim 1 , wherein the group of the surface-modifying compound that binds to the surface of the luminescent nanocrystals contains one or two or more types of atoms selected from the group consisting of sulfur claim 1 , nitrogen claim 1 , oxygen claim 1 , and phosphorus.3. The luminescent nanocrystal complex according to claim 1 , wherein the group of the surface-modifying compound that binds to the surface of the luminescent nanocrystals is any one or more of hydroxy claim 1 , thiol claim 1 , carboxylic acid claim 1 , amine claim 1 , sulfonic acid claim 1 , phosphine claim 1 , phosphine oxide claim 1 , and thioether.5. The luminescent nanocrystal complex according to claim 4 , wherein MGin general formula (i) is a divalent organic group incorporating a cyclic group optionally with a hydrogen atom in the cyclic group substituted with general formula (i-3):{'br': None, 'sup': i2', 'i2', 'i3, 'sub': 'ni2', 'R-(MGSp)-\u2003\u2003(i-3)'}{'sup': 'i2', '(In general formula (i-3) above, MGrepresents a mesogenic group,'}{'sup': 'i3', 'SPrepresents a single bond or ...

Synthesis of aryl coupled bis phenoxides and their use in olefin polymerization catalyst systems with activator-supports

Disclosed herein are methods of making bis(phenol) ligand compounds and transition metal bis(phenolate) compounds. The transition metal bis(phenolate) compounds can be used as components in catalyst systems for the polymerization of olefins.

Synthesis of aryl coupled bis phenoxides and their use in olefin polymerization catalyst systems with activator-supports

Disclosed herein are methods of making bis(phenol) ligand compounds and transition metal bis(phenolate) compounds. The transition metal bis(phenolate) compounds can be used as components in catalyst systems for the polymerization of olefins.

Synthesis of aryl coupled bis phenoxides and their use in olefin polymerization catalyst systems with activator-supports

Disclosed herein are methods of making bis(phenol) ligand compounds and transition metal bis(phenolate) compounds. The transition metal bis(phenolate) compounds can be used as components in catalyst systems for the polymerization of olefins.

Addition polymerizable aromatic sulfonium salts and polymers thereof

Novel polymers having high activity as cationic surface-active agents are prepared by the addition polymerization of ethylenically unsaturated aromatic sulfonium salts, e.g., ##STR1## When such polymers are heated and/or dried, they are irreversibly converted to inert, nonionic residues without the elimination of odorous by-products. The novel sulfonium salt polymers having relatively low molecular weight and low charge density are particularly useful as surfactants or emulsifiers in the emulsion polymerization of ethylenically unsaturated monomers such as styrene, butadiene, alkyl acrylates and the like. The polymers having high molecular weight and high charge density are useful as thickeners and flocculants.

Method of making a high refractive index optical management coating and the coating

A radiation curable composition comprises a heterocyclic acrylate or heterocyclic methacrylate. The composition is curable to make an optical management article such as an optical management coating on a substrate. A method of making an optical management article, comprises forming a radiation curable composition comprising the heterocyclic acrylate or heterocyclic methacrylate on a substrate and curing the composition to form the optical management article.

Method of making a high refractive index optical management coating and the coating

A radiation curable composition comprises a heterocyclic acrylate or heterocyclic methacrylate. The composition is curable to make an optical management article such as an optical management coating on a substrate. A method of making an optical management article, comprises forming a radiation curable composition comprising the heterocyclic acrylate or heterocyclic methacrylate on a substrate and curing the composition to form the optical management article.

一种低聚物及其制备方法、组合物和光学膜

本发明提供了一种低聚物及其制备方法、组合物和光学膜，由乙烯基苯酚与硫，或苯乙烯、乙烯基苯酚与硫反应生成多羟基四苯基噻吩单体，然后再与R基丙烯酰氯反应制得该多官能基的四苯基噻吩丙烯酸低聚物，通过该多官能基的四苯酚噻吩丙烯酸低聚物制得的组合物，可具有良好的成膜效果；通过该组合物所制得的光学膜，可以作为显示器背光模组中的增亮膜，使显示器具有良好的增益效果。除了用来制备增亮膜，亦可应用于制作抗反射膜和3D显示器的柱状透镜膜。

High refractive index, UV-curable monomers and coating compositions prepared therefrom

Disclosed herein are high refractive index monomers that are curable by ultraviolet light. These monomers may be a component of curable compositions useful in the preparation of optical articles. Also disclosed is a method of synthesizing the monomers.

Polyhydric phenols, epoxy resins, epoxy resin composition, and cured products thereof

A resin composition having a light weight, a low viscosity, a low hygroscopicity, a high adhesiveness, an excellent thermal resistance and excellent mechanical properties. The resin comprises a polyhydric phenol of general formula (1) and an epoxy resin of general formula (3).

芳基连接的双酚盐的合成及其用于具有活化剂-载体的烯烃聚合催化剂系统

本文公开的是制备双酚配体化合物和过渡金属双酚盐化合物的方法。过渡金属双酚盐化合物可被用作用于聚合烯烃的催化剂系统中的组分。

Method of synthesis of (s)--1÷1-n,n-dimethyl-3-(1-naphthalinyl- -hydroxy)-3-(2-thienyl)-propaneamine and (s)-±-n,n-dimethyl- -3-(1-naphthalinylhydroxy)-3-(2-thienyl)-propaneamine phosphate

FIELD: organic chemistry, chemical technology, pharmaceutical chemistry. SUBSTANCE: invention relates to asymmetric process of synthesis of key intermediate compound used for synthesis of antidepressant agent dulonectin. Method of synthesis of the above indicated compound involves interaction of (S)-(-)- -N, N-dimethyl-3-(2-thienyl)-3-hydroxypropaneamine with sodium hydride and 1-fluoronaphthalene in an organic solvent. Process is carried out using potassium benzoate or acetate and the end product is isolated as a free form or if necessary as phosphate. EFFECT: accelerated process, enhanced purity, increased yield of the end product. 6 cl, 2 ex 69с1сЬс ПЧ Го (19) РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ ВИ "” 2 127 269 ' (51) МПК 13) Сл С 070 333/20 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 94035996/04, 06.10.1994 (30) Приоритет: 12.10.1993 Ц$ 08/135 032 (46) Дата публикации: 10.03.1999 (56) Ссылки: ЗЦ 1148563 А, 1985. ЕР 0363869 АЛ, 1990. ЕР 0298703 АД, 1989. (98) Адрес для переписки: 103735, Москва, ул.Ильинка, 5/2 СОЮЗПАТЕНТ (71) Заявитель: Эли Лилли энд Компани (1$) (72) Изобретатель: Ричард Алан Бергланд (ЦЗ) (73) Патентообладатель: Эли Лилли энд Компани (0$) (54) СПОСОБ ПОЛУЧЕНИЯ ($)-(+)-М,М-ДИМЕТИЛ-3-(1-НАФТАЛИНИЛОКСИ)-3-(2-ТИЕНИЛ)ПРОПАНАМИНА И ФОСФОРНОКИСЛАЯ СОЛЬ ($)-(+)-М,М-ДИМЕТИЛ-3-(1-НАФТАЛИНИЛОКСИ)-3-(2- ТИЕНИЛ)ПРОПАНАМИНА (57) Реферат: Изобретение относится к области фармацевтической химии и синтетической органической химии и представляет асимметрический процесс синтеза ключевого промежуточного соединения при получении дулосектина - антидепрессантного средства. Способ получения вышеуказанного соединения взаимодействием (5)-(-)-М, М№-ди-метил-3-(2-тиенил)-3-гидроксипропанами на с гидридом натрия и 1- фторнафталином в органическом растворителе отличается тем, что процесс проводят с использованием бензоата калия или ацетата калия и целевой продукт выделяют в свободном виде или, при необходимости, в виде соли ...

Method of producing dithienylalkylamines or salts thereof

There are prepared compounds of the formula <IMAGE> (I) where >A-B- has either the structure >C(OH)-CH2- or the structure >C=CH, Alk is a straight or branched chain C1-C5-alkylene group and Y is a C3-C7-cycloalkyl group, a benzyl group, a methylenedioxybenzyl group, a benzyl group having one, two or three C1-C4-alkyl or C1-C4-alkoxy group substituents, a C1-C6-alkyl group, or a C1-C6-alkyl group substituted by an amino group, a di C1-C4-alkylamino group, a mono C1-C4-alkyl-amino group, a morpholino group, a piperazino group or a 4-(C1-C4-alkyl)-piperazino group, or Y is <IMAGE> where R is hydrogen or a C1-C4-alkyl group and T is hydrogen or a C2-C6-alkanoyl group or where -NHY is <IMAGE> where R' is hydrogen, phenyl, phenyl substituted once or twice by C1-C4-alkyl groups, a C1-C4-alkoxy group or by halogen atoms, a C1-C6-alkyl group, a C1-C4-hydroxyalkyl group or a phenalkyl group whose alkyl portion consists of 1-4 carbon atoms or such a phenalkyl group containing 1 to 3 C1-C4-alkoxy group substituents or when Alk has 2 to 5 carbon atoms the group -NHY is a di-C1-C4-alkylamino group or the group -NH-CH(R)-CH(OH)-C6H5 and salts thereof. The compounds are effective in improving peripheral and cerebral circulation. There are also produced intermediate compounds of formula (II) where NHY is replaced by chlorine, bromine or iodine.

Synthesis of aryl coupled bis phenoxides and their use in olefin polymerization catalyst systems with activator-supports

Disclosed herein are methods of making bis(phenol) ligand compounds and transition metal bis(phenolate) compounds. The transition metal bis(phenolate) compounds can be used as components in catalyst systems for the polymerization of olefins.

Method of preparing /3,3-di(thienyl-3)-3-oxypropyl/-(1-phenyl-1-oxypropyl-2)-amine or /3,3-di(thienyl-3)propen-2-yl/-(1-phenyl-1-oxypropyl-2-)-amine or their salts

[1,1-dithien-(3)-yl-1-hydroxy-(3)-propyl]-[1-phenyl-1-hydroxy-(2)-prop yl]-amine is prepared by condensing thien-(3)-yl lithium with a beta -halogen propionic acid alkyl ester of the formula <IMAGE> (II) where R is a lower alkyl group and Hal is chlorine, bromine or iodine, in an inert medium at a temperature below -50 DEG C. to form a compound of the formula <IMAGE> (III) which is then reacted with 2-amino-1-hydroxy-1-phenylpropane in an inert medium in the presence of a basic compound. The product cn be converted to [1,1-dithien-(3)-yl-(1)-propen-(3)-yl]-[1-phenyl-(2)-propyl]-amine by dehydration.

Iron(ii) catalysts containing tridentate pnp ligands, their synthesis, and use thereof

一种希夫碱稀土镱碘化物及其制备方法和应用

本发明公开了一种希夫碱稀土镱碘化物及其制备方法和应用。所述的希夫碱稀土镱碘化物为N‑(4‑异丙基‑2，6‑二（二苯甲基）苯基)‑3,5‑二叔丁基‑2‑氧希夫碱稀土镱碘化物，其制备方法为：无水无氧条件下，N‑(4‑异丙基‑2，6‑二（二苯甲基）苯基)‑3,5‑二叔丁基‑2‑羟基苯甲醛亚胺和氢化钾反应得到相应钾盐，再与碘化镱反应，得到黄色晶体，即为N‑(4‑异丙基‑2，6‑二（二苯甲基）苯基)‑3,5‑二叔丁基‑2‑氧希夫碱稀土镱碘化物。本发明的希夫碱稀土镱碘化物的合成简单，分离提纯方便，结构明确，且收率高；其作为催化剂催化醛或者酮与频哪醇硼烷反应的活性高，底物普适性宽。

4,4 '-diaryl -3,3 '-union II thiophene derivant, synthetic method and its application

本发明公开了一种4,4’‑二芳基‑3,3’‑联二噻吩衍生物、合成方法及其应用。本发明的衍生物通过将4,4’‑二溴‑3,3’‑联二噻吩和芳基硼酸酯底物Ar‑B(OH) 2 发生Suzuki偶联反应得到；其中：所述Ar为苯基，取代的苯基、1‑萘基、2‑萘基或蒽基等。它们具有良好的光学性能，可作为有机小分子光电材料，应用于有机染料、染料敏化太阳能电池、有机发光二极管、有机场效应晶体管和有机半导体材料领域。

Preparation method of canagliflozin intermediates

本发明涉及药物中间体制备技术领域，具体公开了一种坎格列净中间体的制备方法，能够制备高纯度2-(4-氟苯基)-5[(5-卤代-2-甲基苯基甲醇)]噻吩，包括下列步骤：采用对氟卤苄和3-卤代丙烯醛为原料，在硫试剂存在下，得到2-对氟苯基噻吩；所得2-对氟苯基噻吩与5-卤代-2-甲基苯甲醛在正丁基锂条件下得到产物2-(4-氟苯基)-5-[(5-卤代-2-甲基苯基甲醇)]噻吩。相对于现有技术,本发明方法原料易得,收率高,反应条件易控制,所得产品纯度高,反应更加稳定,更易于商业化生产。

Catalytic hydrogeneration of carbon-heteroatom double bonds

一种催化氢化碳-杂原子双键的方法，具体是不对称催化氢化简单酮的方法，所述方法包括在氢化催化剂和碱的存在下使所述被作用物与氢反应，其特征在于所述氢化催化剂各自为具有单膦配体和二齿P-N配体的5-配位钌络合物。

N-sulfonylglycinealkynyloxyphenethylamide derivatives eliciting bactericidal activity

FIELD: organic chemistry, herbicides. SUBSTANCE: invention relates to new N- sulfonylglycinealkynyloxyphenethylamide derivatives of the formula (I): wherein n = 1; R 1 means C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, C 2 -C 6 -alkenyl, C 1 -C 6 -haloidalkyl or group NR 11 R 12 wherein R 11 and R 12 each of one another means hydrogen atom, C 1 -C 6 -alkyl; R 2 means hydrogen atom; R 3 means C 1 -C 8 -alkyl; R 4 ,R 5 ,R 6 ,R 7 have similar or different values and each independently of one another means hydrogen atom, C 1 -C 4 -alkyl; R 8 means C 1 -C 6 -alkyl; A means C 1 -C 6 -alkylene; B means phenyl optionally substituted with 1-3 substituents that can be similar or different and taken among group including: C 1 -C 8 -alkyl, C 1 -C 8 -haloidalkyl, C 1 -C 8 -alkoxy-group, C 1 -C 8 -haloidalkoxy-group, C 2 -C 8 -alkanoyl, halogen atom, C 1 -C 8 -alkaoxycarbonyl, nitro-group; or naphthyl or thienyl. Compounds elicit herbicide activity for prevention and control of phytopathogenic microorganisms. EFFECT: valuable agriculture properties of compounds. 5 cl, 10 tbl, 6 ex ЗЕ сСсСс ПЧ сэ (19) РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ ВИ” 2 221 778‘ (51) МПК? 13) С2 С 07 С 311/06, 311/14, 307/06, С 070 333/24, А 01 М 41/06, 43/10 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 2000104513/04, 04.08.1998 (24) Дата начала действия патента: 04.08.1998 (30) Приоритет: 06.08.1997 СН 1864/97 (43) Дата публикации заявки: 21.02.2002 (46) Дата публикации: 20.01.2004 (56) Ссылки: МО 95/30651 АЛ, 16.11.1995. МО 97/1466 АЛ, 24.04.1997. $Ц 759046 А, 23.08.1980. (85) Дата перевода заявки РСТ на национальную фазу: 06.03.2000 (86) Заявка РСТ: ЕР 98/04849 (04.08.1998) (87) Публикация РСТ: М/О 99/07674 (18.02.1999) (98) Адрес для переписки: 101000, Москва, М.Златоустинский пер., 10, кв.15, ЕВРОМАРКПАТ, пат.пов. И.А.Веселицкой (72) Изобретатель: ЦЕЛЛЕР Мартин (СН), ЖАНГЕНА Андрэ (СН) (73) Патентообладатель: . ЗИНГЕНТА ПАРТИСИПЕИЙШНС (СН) (74) Патентный поверенный ...

Synthesis of aryl coupled bis phenoxides and their use in olefin polymerization catalyst systems with activator-supports

Asymmetric synthesis of duroxin intermediates

METHOD OF METALLORGANIC PRODUCTION OF ORGANIC INTERMEDIATE PRODUCTS

ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß (19) RU (51) ÌÏÊ 7 (11) 2004 114 273 (13) A C 07 F 1/02 ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ, ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ (12) ÇÀßÂÊÀ ÍÀ ÈÇÎÁÐÅÒÅÍÈÅ (21), (22) Çà âêà: 2004114273/04, 02.10.2002 (71) Çà âèòåëü(è): ÊËÀÐÈÀÍÒ ÃÌÁÕ (DE) (30) Ïðèîðèòåò: 12.10.2001 DE 10150615.5 (72) Àâòîð(û): Ìîéäò Àíäðåàñ (DE) (85) Äàòà ïåðåâîäà çà âêè PCT íà íàöèîíàëüíóþ ôàçó: 12.05.2004 (74) Ïàòåíòíûé ïîâåðåííûé: Àãóðååâ Àëåêñàíäð Ïàâëîâè÷ (86) Çà âêà PCT: EP 02/11042 (02.10.2002) Àäðåñ äë ïåðåïèñêè: 103735, Ìîñêâà, óë. Èëüèíêà, 5/2, ÎÎÎ "Ñîþçïàòåíò", ïàò.ïîâ. À.Ï.Àãóðååâó R U Ôîðìóëà èçîáðåòåíè 1. Ñïîñîá ïîëó÷åíè ñîåäèíåíèé àðèëëèòè ôîðìóë (IV) è (VI) âçàèìîäåéñòâèåì ãàëîãåííûõ ñîåäèíåíèé (I) ñ ìåòàëëè÷åñêèì ëèòèåì ñ ïîëó÷åíèåì ñîåäèíåíè ëèòè ôîðìóëû (II) è ïîñëåäóþùèì âçàèìîäåéñòâèåì ñîåäèíåíè ëèòè (II) àðîìàòè÷åñêèìè ñîåäèíåíè ìè ôîðìóë (III) è/èëè (V) ñ äåïðîòîíèðîâàíèåì è îáðàçîâàíèåì àðîìàòè÷åñêèõ ñîåäèíåíèé ëèòè (IV) è/èëè (VI) (óðàâíåíèå I), ïðè÷åì ðåàêöè ïðîâîäèòñ â âèäå îäíîêîìïîíåíòíîé: Ñòðàíèöà: 1 RU A 2 0 0 4 1 1 4 2 7 3 A (54) ÑÏÎÑÎÁ ÌÅÒÀËËÎÐÃÀÍÈ×ÅÑÊÎÃÎ ÏÎËÓ×ÅÍÈß ÎÐÃÀÍÈ×ÅÑÊÈÕ ÏÐÎÌÅÆÓÒÎ×ÍÛÕ ÏÐÎÄÓÊÒΠ2 0 0 4 1 1 4 2 7 3 (87) Ïóáëèêàöè PCT: WO 03/033503 (24.04.2003) R U (43) Äàòà ïóáëèêàöèè çà âêè: 27.10.2005 Áþë. ¹ 30 2 0 0 4 1 1 4 2 7 3 R U A Ñòðàíèöà: 2 2 0 0 4 1 1 4 2 7 3 A R U (óðàâíåíèå I), ãäå R - ìåòèë, ïåðâè÷íûå, âòîðè÷íûå èëè òðåòè÷íûå àëêèëüíûå îñòàòêè ñ 2-12 àòîìàìè óãëåðîäà, çàìåùåííûé àëêèë, ñîäåðæàùèå îñòàòîê èç ãðóïïû: ôåíèë, çàìåùåííûé ôåíèë, àðèë, ãåòåðîàðèë, àëêîêñèë, äèàëêèëàìèí, àëêèëòèî, çàìåùåííûé èëè íåçàìåùåííûé öèêëîàëêèë ñ 3-8 àòîìàìè óãëåðîäà, Hal - ôòîð, õëîð, áðîì èëè éîä, X1-4 îçíà÷àþò, íåçàâèñèìî äðóã îò äðóãà, óãëåðîä, ãðóïïà Õ1-4 R1-4 ìîæåò îçíà÷àòü àçîò, èëè ñîîòâåòñòâåííî äâà ðàñïîëîæåííûõ ð äîì îñòàòêà X1-4 R1-4 âìåñòå ìîãóò îçíà÷àòü Î, S, NH èëè NR', ïðè ýòîì R' îçíà÷àåò àëêèë ñ 1-5 àòîìàìè óãëåðîäà, SO2-ôåíèë, SO2-pòîëóèë èëè áåíçîèë, îñòàòêè R1-4 è îñòàòîê Z îçíà÷àþò çàìåñòèòåëè èç ãðóïïû âîäîðîä, ...

A pharmaceutical composition containing 2-hydroxy-7-methyl octahydrophenanthrene derivative as an estrogen receptor ligand or a pharmaceutically acceptable salt thereof as an effective component

하기 화학식 I, II 의 화합물 또는 이의 약학적으로 허용가능한 에스테르, 아미드 또는 카바메이트 염, 및 상기 에스테르, 아미드, 카바메이트 염의 용매 화합물을 포함하는 용매 화합물을 제공한다. 또한, 본 발명은 에스트로겐 수용체 활성과 관련된 질환 또는 장애와 관련된 상태의 치료 또는 예방에 있어서의 상기 화합물의 용도 및 상기 화합물을 포함하는 약학 조성물을 제공한다. 상기 화학식Ⅰ 및 II 에서, R 1 , R 2 , R 3 , R 4 는 본 명세서에서 정의한 바와 같다. There is provided a solvate comprising a compound of formula (I), (II) or a pharmaceutically acceptable ester, amide or carbamate salt thereof, and a solvate of said ester, amide, carbamate salt. The invention also provides the use of such compounds in the treatment or prevention of conditions associated with diseases or disorders associated with estrogen receptor activity and pharmaceutical compositions comprising such compounds. In Formulas I and II above, R 1 , R 2 , R 3 , R 4 are as defined herein.

Method for preparing metalloorganic organic intermediate compounds

FIELD: chemistry of metalloorganic compounds, chemical technology. SUBSTANCE: invention describes an improved method for synthesis of lithium-organic compounds providing in situ step in preparing aryl-lithium compounds of the formula IV and/or VI that compounds are subjected the for interaction with an electrophilic reagent. Compounds of the formula IV and/or V: are synthesized by interaction of halides of the formula I with metallic lithium to yield compound of the formula II followed by its interaction with compounds of the formula III and/or V, deprotonation to form lithium-containing compounds of the formula IV and/or VI (equation I) wherein R means -CH 3 , primary, secondary or tertiary (C 2 -C 8 )-alkyl, unsubstituted (C 5 -C 10 )-cycloalkyl; X 1-4 means hydrogen atom (H), two residues near with X 1-4 R1-R4 form in common oxygen (O) or sulfur (S) atoms; R1-R4 and residue Z mean H, -CH 3 , alkoxy, alkoxyalkyl, substituted acyclic alkyl or F; Hal means F, Br, Cl. Method is inexpensive, shows high yield and purity degree of end products. The 1-st step: synthesis of a base: . The 2-d step: deprotonation of substrate: . EFFECT: improved method of synthesis. 9 cl, 6 ex ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß RU (19) (11) 2 321 591 (13) C2 (51) ÌÏÊ C07F 1/02 (2006.01) ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ, ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ (12) ÎÏÈÑÀÍÈÅ ÈÇÎÁÐÅÒÅÍÈß Ê ÏÀÒÅÍÒÓ (21), (22) Çà âêà: 2004114273/04, 02.10.2002 (72) Àâòîð(û): Ìîéäò Àíäðåàñ (DE) (24) Äàòà íà÷àëà îòñ÷åòà ñðîêà äåéñòâè ïàòåíòà: 02.10.2002 (73) Ïàòåíòîîáëàäàòåëü(è): ÀÐÕÈÌÈÊÀ ÃÌÁÕ (DE) R U (30) Êîíâåíöèîííûé ïðèîðèòåò: 12.10.2001 (ïï.1-9) DE 10150615.5 (43) Äàòà ïóáëèêàöèè çà âêè: 27.10.2005 (45) Îïóáëèêîâàíî: 10.04.2008 Áþë. ¹ 10 2 3 2 1 5 9 1 (56) Ñïèñîê äîêóìåíòîâ, öèòèðîâàííûõ â îò÷åòå î ïîèñêå: WO 0064905 À, 02.11.2000. SU 667547 A1, 15.06.1979. (85) Äàòà ïåðåâîäà çà âêè PCT íà íàöèîíàëüíóþ ôàçó: 12.05.2004 2 3 2 1 5 9 1 R U (87) Ïóáëèêàöè PCT: WO 03/033503 (24.04.2003) C 2 C 2 (86) Çà âêà PCT: EP 02/ ...

Microbicidal N-sulfonylglycin alkynyloxyphenethyl amide derivatives

본 발명은 하기 화학식 I의 신규한 농약 활성 화합물 및 가능하게는 이의 이성체 및 이성체 혼합물에 관한 것이다. 본 발명의 신규한 화합물은 식물-보호 특성을 가지며, 식물병원성 미생물에 의한 침입으로부터 식물을 보호하는데 적합하다. The present invention relates to novel agrochemically active compounds of the formula (I) and possibly to isomers and mixtures thereof. The novel compounds of the present invention have plant-protective properties and are suitable for protecting plants from invasion by phytopathogenic microorganisms. 화학식 I Formula I 위의 화학식 I에서, In Formula I above, n은 0 또는 1의 수이고; n is a number of 0 or 1; R 1 은 치환되지 않거나 C 1 -C 4 알콕시, C 1 -C 4 알킬티오, C 1 -C 4 알킬설포닐, C 3 -C 8 사이클로알킬, 시아노, C 1 -C 6 알콕시카보닐, C 3 -C 6 알케닐옥시카보닐 또는 C 3 -C 6 알키닐옥시카보닐에 의해 치환될 수 있는 C 1 -C 12 알킬; C 3 -C 8 사이클로알킬; C 2 -C 12 알케닐; C 2 -C 12 알키닐; C 1 -C 12 할로알킬; 또는 그룹 NR 11 R 12 (여기서, R 11 및 R 12 는 각각 독립적으로 수소 또는 C 1 -C 6 알킬이거나 함께 테트라- 또는 펜타-메틸렌이다)이며; R 1 is unsubstituted or C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfonyl, C 3 -C 8 cycloalkyl, cyano, C 1 -C 6 alkoxycarbonyl, C 1 -C 12 alkyl which may be substituted by C 3 -C 6 alkenyloxycarbonyl or C 3 -C 6 alkynyloxycarbonyl; C 3 -C 8 cycloalkyl; C 2 -C 12 alkenyl; C 2 -C 12 alkynyl; C 1 -C 12 haloalkyl; Or group NR 11 R 12 , wherein R 11 and R 12 are each independently hydrogen or C 1 -C 6 alkyl or together are tetra- or penta-methylene; R 2 및 R 3 은 각각 독립적으로 수소; C 1 -C 8 알킬; 하이드록시, C 1 -C 4 알콕시, 머캅토 또는 C 1 -C 4 알킬티오에 의해 치환된 C 1 -C 8 알킬; C 3 -C 8 알케닐; C 3 -C 8 알키닐; C 3 -C 8 사이클로알킬; C 3 -C 8 사이클로알킬-C 1 -C 4 알킬이거나; R 2 와 R 3 두 그룹은 이들이 결합되어 있는 탄소 원자와 함께 3 내지 8원 환을 형성하고; R 2 and R 3 are each independently hydrogen; C 1 -C 8 alkyl; C 1 -C 8 alkyl substituted by hydroxy, C 1 -C 4 alkoxy, mercapto or C 1 -C 4 alkylthio; C 3 -C 8 alkenyl; C 3 -C 8 alkynyl; C 3 -C 8 cycloalkyl; C 3 -C 8 cycloalkyl-C 1 -C 4 alkyl; Two groups R 2 and R 3 together with the carbon atom to which they are attached form a 3-8 membered ring; R 4 , R 5 , R 6 및 R 7 은 동일하거나 상이하며, 각각 독립적으로 수소 또는 C 1 -C 4 알킬이며; R 4 , R 5 , R 6 and R 7 are the same or different and ...

METHOD FOR PRODUCING SQUARE CLAMP ON 4- (THIENYLCARBONYL) PHENYL SQUARE CLAMP TO -PROPIONIC ACID

Method for continuously preparing α -keto ester by using microfluid chip reactor

本发明公开了一种利用微流体芯片反应器连续制备α‑酮酸酯的方法，它是将乙酰苯类化合物、醇、碘和DBU溶于DMF中，得到均相溶液A；将对应比例的叔丁醇过氧化氢水溶液DMF中，得到均相溶液B；配置饱和的硫代硫酸钠溶液用于反应液的淬灭。在将均相溶液A、均相溶液B和淬灭液注入到微流体芯片，反应物在芯片中进行混合、反应、淬灭后，经后处理得到α‑酮酸酯。与现有技术相比，本发明具有操作简便、安全，高效，可连续化制备α‑酮酸酯，反应条件温和，而且具有良好的底物普适性。

Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

The invention relates to the use of derivatives of E-type prostaglandins as EP 2 agonists, in general, and, in particular as ocular hypotensives. The PGE derivatives used in accordance with the invention are represented by the following formula I: wherein the hatched segment represents an α bonds, the solid triangle represents a β bond, the wavy segments represent α or β bond, dashed lines represent a double bond or a single bond, R 3 is heteroaryl or a substituted heteroaryl radical, R 1 and R 2 are independently selected from the group consisting of hydrogen or a lower alkyl radical having up to six carbon atoms, or a lower acyl radical having up to six carbon atoms, R is selected from the group consisting of CO 2 R 4 , CONR 4 2 , CH 2 OR 4 , CONR 4 SO 2 R 4 , P(O)(OR 4 ) and wherein R 4 is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms and n is 0 or an integer of from 1 to 4.

ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

The invention relates to the use of derivatives of E-type prostaglandins as EP 2 agonists, in general, and, in particular as ocular hypotensives. The PGE derivatives used in accordance with the invention are represented by the following formula I: wherein the hatched segment represents an α bonds, the solid triangle represents a β bond, the wavy segments represent α or β bond, dashed lines represent a double bond or a single bond R, , R 1 , R 2 and R 3 are as defined in the specification.

Process for preparing 1,2, 4-oxadiazole derivatives

本发明提供一种通过简单的程序和高生产效率进行的1,2,4‑噁二唑衍生物的制备方法。本发明涉及一种由下式(A)表示的1,2,4‑噁二唑衍生物的制备方法，该方法包括使由下式(B)表示的化合物和由下式(C)表示的化合物在碱性化合物存在下反应，

Suzuki reaction method of arylboronic acid/boric acid ester containing large steric hindrance substituent

本发明提供了一种含有大位阻取代基芳基硼酸/硼酸酯的铃木反应方法，所述反应具有式I所示的特点，其中Ar代表具共轭结构的化合物；R 1 代表含有2‑18个碳原子烷基，Y 1 代表含有1‑18个碳原子烷基、烷氧基、烷硫基、酯基等基团；B代表二杂氧戊硼烷基团或硼酸基。本发明所提供的方法中选用乙二醇二甲醚、二乙二醇二甲醚等合适的溶剂与常用的钯催化剂搭配作为反应体系，有效地解决了具有大位阻基团的铃木反应难以进行的问题。

Fluoroalkylating agent

FIELD: organic chemistry. SUBSTANCE: invention relates to fluoroalkylating agent of formula (1) wherein R 1 represents a C1-C4 perfluoroalkyl group; R 2 and R 3 are each independently a C1-C4 alkyl group or a phenyl group; Y 1 , Y 2 , Y 3 and Y 4 are each independently a hydrogen atom, a halogen atom or a nitro group; and X - is I - , BF 4 - , CF 3 SO 3 - , CH 3 OSO 3 - or C 2 H 5 OSO 3 - provided that following cases (i) and (ii) are excluded: (i) R 1 is a trifluoromethyl group, R 2 and R 3 are each a methyl group, Y 1 , Y 2 , Y 3 and Y 4 are each a hydrogen atom, and X - is I - ; and (ii) R 1 is a trifluoromethyl group, R 2 and R 3 are each a methyl group, Y 1 is a hydrogen atom, Y 2 is a methyl group, Y 3 is a methyl group, Y 4 is an atom hydrogen, and X - is I - . Invention also relates to a compound of formula (1), use thereof as a fluoroalkylating agent, as well as a method of producing compounds of formulas (3) and (5) based on use of a fluoroalkylating agent of formula (1). , , EFFECT: obtaining a fluoroalkylating agent, use of which in a fluoroalkylation reaction enables to conduct the process in mild conditions and without special equipment. 19 cl, 19 tbl, 136 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) (19) RU (11) (13) 2 716 008 C2 (51) МПК C07D 235/10 (2006.01) C07D 213/30 (2006.01) C07D 333/16 (2006.01) C07C 29/38 (2006.01) C07C 319/14 (2006.01) C07C 319/20 (2006.01) C07C 319/26 (2006.01) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК C07D 235/10 (2020.02); C07D 213/30 (2020.02); C07D 333/16 (2020.02); C07C 29/38 (2020.02); C07C 319/14 (2020.02); C07C 319/20 (2020.02); C07C 319/26 (2020.02) (21)(22) Заявка: 2016149299, 24.06.2015 24.06.2015 (73) Патентообладатель(и): КУМИАЙ КЕМИКАЛ ИНДАСТРИ КО., ЛТД. (JP) Дата регистрации: 05.03.2020 26.06.2014 JP 2014-131688 (43) Дата публикации заявки: 27.07.2018 Бюл. № 21 (45) Опубликовано: 05.03.2020 Бюл. № 7 (86) Заявка PCT: JP 2015/068127 (24.06.2015) C 2 C 2 (85) Дата начала ...

Fluoroalkylating agent

РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2016 149 299 A (51) МПК C07D 235/10 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2016149299, 24.06.2015 (71) Заявитель(и): КУМИАЙ КЕМИКАЛ ИНДАСТРИ КО., ЛТД. (JP) Приоритет(ы): (30) Конвенционный приоритет: 26.06.2014 JP 2014-131688 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 26.01.2017 R U (43) Дата публикации заявки: 27.07.2018 Бюл. № 21 (72) Автор(ы): КАВАДЗОЕ Кентаро (JP), ЙОСИОКА Котаро (JP) (86) Заявка PCT: (87) Публикация заявки PCT: WO 2015/199109 (30.12.2015) R U (54) ФТОРАЛКИЛИРУЮЩИЙ АГЕНТ (57) Формула изобретения 1. Фторалкилирующий агент, представленный общей формулой (1): A 2 0 1 6 1 4 9 2 9 9 A Адрес для переписки: 129090, Москва, ул. Б. Спасская, 25, стр. 3, ООО "Юридическая фирма Городисский и Партнеры" 2 0 1 6 1 4 9 2 9 9 JP 2015/068127 (24.06.2015) где R1 представляет собой C1-C8 фторалкильную группу; R2 и R3 представляют собой, каждый, независимо C1-C12 алкильную группу, которая может содержать один или несколько заместителей, C2-C6 алкенильную группу, которая может содержать один или несколько заместителей, C2-C6 алкинильную группу, которая может содержать один или несколько заместителей, C3-C8 циклоалкильную группу, которая может содержать один или несколько заместителей или C6-C10 арильную группу, которая может содержать один или несколько заместителей; Стр.: 1 R1 представляет собой C1-C4 перфторалкильную группу; R2 и R3 представляют собой, каждый, независимо C1-C4 алкильную группу или фенильную группу; Y1, Y2, Y3 и Y4 представляют собой, каждый, независимо атом водорода, атом галогена, нитрогруппу, цианогруппу, C1-C4 алкильную группу или C1-C4 галогеналкильную группу; и X- представляет собой Cl-, Br-, I-, A R U BF4-, CF3SO3-, HOSO3-, CH3OSO3- или C2H5OSO3-. 3. Агент по п.1, где R1 представляет собой трифторметильную группу или пентафторэтильную группу; R2 и R3 представляют собой, каждый, независимо метильную группу, этильную ...

Method for preparing β -carbonyl sulfone

本发明公开了一种制备β‑羰基砜的方法。以α‑羰基重氮化合物和芳基亚磺酸钠为反应底物，以廉价的硝酸银为最优催化剂，1,10‑菲啰啉为配体，过硫酸钾为氧化剂，在乙腈与水的混合溶剂中经过偶联反应得到β‑羰基砜化合物。与现有技术相比较，本发明方法具有以下优点：反应底物范围广，反应时间短，反应产率比较高，反应条件温和等优点。本发明使用无毒无害的试剂为反应原料，对环境没有危害，符合当代绿色化学发展的要求。反应后处理比较简单，便于分离提纯。此外，该反应能够实现克级规模合成，为实际应用奠定基础。

Heteroaromatic acetylenes useful as antihypertensive agents

Heterocyclic acetylenes of the formula (I): ##STR1## wherein Y is alkyl, alkoxy, alkoxyalkyl, chloro, fluoro, bromo or carboxamidoalkyl and R 1 is hydrogen, alkyl, alkoxy, alkylthio, alkoxycarbonyl, chloro, fluoro or dialkylamino, m is 0-2, R 2 is branched alkyl and Het is an aromatic heterocycle. The acetylenes are useful in treating hypertension and/or angina.

Process for the purification of thiophenes

本发明涉及一种提纯在室温下是液体的通式(I)噻吩的方法，式中，在室温下是液体的通式(I)噻吩在低于所述噻吩的熔融温度的温度下从至少一种溶剂中以固体形式沉淀出来，还涉及通过该方法提纯的噻吩及其应用。

N-bis (3-thienylpropyl) phenethylamines -with coronary vasodilator - activity

Cpds. are of formula: their isomers and acid-addn. salts (X = thienyl opt. substd. with one or more alkyls; A . B = C(OH)CH2 or C=CH- in which one of the H atoms of B or the CH2 gp. between B and -NR1 may be replaced by alkyl; R1 = H, alkyl; R2 = H, alkyl; R3 = H, OH; R4, R5 = H, OH, halogen, alkyl, haloalkyl, alkoxy). The alkyl substition of the B and CH2 gps. are an addn. to the parent patent.

Tetrahydro-thieno-pyridine derivs. prepn. - by cyclizing 2-(2-aminoethyl)thiophenes with formaldehyde (BE060876)

Thienopyridine derivs. of formula (I) (where R1 is opt. substd. alkyl, aryl or aralkyl; and R2 and R3 are H, lower alkyl, aryl or heterocyclyl), e.g. 5-(2-chlorobenzyl-4,5,6,7-tetrahydrothieno 3,2-c pyridine, are prepd. by (a) reacting cpds. of formula (II) (where X is H, an alkali metal or a gp. Mg-Y in which Y is halogen) with a cpd. Hal-SO2-R4 (III) (where Hal is halogen and R4 is opt. substd. alkyl, aryl or aralkyl); (b) reacting the resulting cpd. of formula (IV) with an amine R1-NH2 (V); and (c) cyclising the resulting cpd. of formula (VI) with formaldehyde. (I) are pharmaceuticals.

Heterocyclo bis methylene isothioureas - analgesics and antiinflammatories, from thiourea and bis halo methyl heterocycle, pref. a thiadiazole

Patent FR2377396B1

Method of obtaining thieno (3,2-c) pyridine derivatives or salts thereof

Phenalkylamines and process

Patent FR2105223A1

SUBSTITUTED THIOPHENES, CONDUCTIVE POLYMERS DERIVED FROM SUCH THIOPHENES, PROCESS FOR OBTAINING SAME, AND DEVICES CONTAINING THESE POLYMERS

CONDUCTIVE POLYMERS DERIVED FROM AROMATIC HETEROCYCLES SUBSTITUTED BY AN ETHER-TYPE GROUP, PROCESS FOR OBTAINING SAME, DEVICES CONTAINING SUCH POLYMERS AND MONOMERS FOR OBTAINING SUCH POLYMERS

Patent FR1589663A

PROCESS FOR PREPARING SYN ISOMERS OF 3,7-CEPHEM-4-CARBOXYLIC 3,7-DISUBSTITUTED ACID COMPOUNDS AND NEW PRODUCTS THUS OBTAINED, WITH ANTIBACTERIAL ACTIVITY

Syn isomers of alkoxy-imino acetamido-cephalosporins

(A)Syn isomers of the cephalosporin oximes of formula (I) and their pharmaceutically acceptable salts are new. In the formula, R1 is (II), (III) or (IV); R5 = H, halo, NO2, OH, lower alkoxy or acyloxy; R6 = OH (lower alkoxy, acyloxy acylamino or di(lower alkyl) amino; R7 is opt.protected amino, OH or lower alkyl; R8 = lower alkyl; R9 = opt.protected imino or oxo; R2 = aliphatic hydrocarbyl opt. with >=1 substits; R3 = opt. protected carboxy; R4 = acyloxymethyl, hydroxymethyl, formyl or heterocyclic thiomethyl opt. with >=1 substits., R3 + R4 are together -COOCH2. (I) are antibacterials effective against Gram positive and negative species, and useful in human and veterinary medicine. A typical cpd. (1 of 27) is 7-/2-methoxyimino-2-(3-hydroxyphenyl) acetamido/-3-(1-methyl-1H-te trazol-5-yl) thiomethyl-3-cephem-4-carboxylic acid, prepd. from corresp. 7-amino cpd. and 2-methoxyimino-2-(3-hydroxyphenyl)acetic acid

SUBSTITUTED THIOPHENES, CONDUCTIVE POLYMERS DERIVED FROM THIOPHENES, PROCESS FOR THEIR PREPARATION AND DEVICES CONTAINING THESE POLYMERS

Thiophènes substitués de formule générale : (CF DESSIN DANS BOPI) dans laquelle : - R représente un atome d'hydrogène, un atome d'halogène ou un groupement aliphatique comptant de 1 à 4 atomes de carbone, - X représente un atome d'hydrogène ou un atome de fluor, - Y représente un groupement aliphatique ou aromatique au moins partiellement fluoré, - m représente un nombre entier égal ou supérieur à 2, - n représente un nombre entier tel que 0 =< n =< 7. L'invention concerne également les polymères conducteurs d'électricité contenant des unités récurrentes dérivées de monomères choisis parmi les thiophènes substitués. Substituted thiophenes of general formula: (CF DRAWING IN BOPI) in which: - R represents a hydrogen atom, a halogen atom or an aliphatic group containing from 1 to 4 carbon atoms, - X represents a hydrogen atom or a fluorine atom, - Y represents an at least partially fluorinated aliphatic or aromatic group, - m represents an integer equal to or greater than 2, - n represents an integer such that 0 = <n = <7. The invention also relates to electrically conductive polymers containing repeating units derived from monomers chosen from substituted thiophenes.

2-ALCOXYAMINO-2- (AMINO-1,3-THIAZOLYL) ACETICS DERIVATIVES AND THEIR USE

NOVEL PARA- (ARYL (ALKYL OR ALCENYL) AMINO) -BENZOIC ACID DERIVATIVES AND THEIR USE AS ANTILIPIDEMIC AGENTS

Nouveaux dérivés d'acide p-Øaryl(alkyl ou alcényl) aminoõ-benzoïque de formule : New p-Øaryl (alkyl or alkenyl) aminoõ-benzoic acid derivatives of formula:

Patent FR7789M

Patent FR2105223B1

CONDUCTIVE POLYMERS DERIVED FROM AROMATIC HETEROCYCLES SUBSTITUTED BY AN ETHER-TYPE GROUPING, PROCESS FOR OBTAINING SAME AND DEVICES CONTAINING SUCH POLYMERS

URICOSURIC AND HYPOURICEMIC COMPOSITION

Patent FR2382449B1

PROCESS FOR THE PREPARATION OF (1,1-DITHIENYL- (3) -1-HYDROXYPROPYL- (3)) - (1-PHENYL-1-HYDROXYPROPYL- (2)) - AMINE AND (1,1-DITHIENYL- ( 3) -PROPEN- (1) -YL- (3)) - (1-PHENYL-PROPYL- (2)) - AMINE

On prépare la Øl,l-dithiényl-(3)- 1-hydroxypropyl-(3)õ-Ø1-phényl-1-hydroxypropyl-(2)õ-amine (formule I) en condensant, dans un milieu inerte, à une température inférieure à - 50 degrés C, un lithium-thiényle-(3) avec un ester alcoylique d'acide beta -halogéno-propionique de formule (II, puis en faisant reagir le composé obtenu, de formule (III), avec le 2-amino-1-phényl-propanol-(1), dans un milieu inerte et en présence d'un compose basique. On déshydrate le produit de réaction de formule I obtenu pour obtenir la Ø1,1-dithiényl-(3)-propén-(1)-yl-(3)õ-Ø1- phényl-propyl-(2)õ-amine. Le composé de formule I possède d'intéressantes activités pharmacodynamiques. En outre, c'est un produit intermédiaire important pour la préparation de la Ø1,1-dithiényl-(2)-propén- (1)-yl-(3)õ-Ø1-phényl- l-hydroxypropyl-(2)õ-amine qui possède elle aussi une forte activité pharmacodynamique.

Polyhydric phenols, epoxy resins, epoxy resin composition, and cured products thereof

本发明的目的是提供具备低粘度、低吸湿性、高粘合性和耐热性良好等特性的机械物性良好的轻质树脂组合物。所述树脂组合物中包含式(1)表示的多元酚类化合物和式(3)表示的环氧树脂。

Analogous process for the preparation of an amidine or an acid addition salt thereof.

The phosphoric acid salt of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propa namine and its preparation

Prepn. of S-(+)-N,N-dimethyl-3-(1-naphthyloxy)-3-(2- thienyl)-propanamine (I) comprises reacting (S)-(-)-N,N- dimethyl-3-(2-thienyl)-3-hydroxy-propanamine (II) with sodium hydride, potassium benzoate or acetate and 1-fluoro-naphthalene (III) in an organic solvent. (II) and NaH are dissolved in the solvent, the potassium cpd. is added with stirring, then (III) is added with stirring. (I) is isolated as the phosphoric acid salt. Typically the solvent is DMSO, the use amt. of NaH is 1 equiv/equiv. (II), the use amt. of potassium cpd. is 0.05-1 equiv./equiv. (II) and stirring is at 10-35 [deg] C for 5-60 min. Use amt. of (III) is 1-25% excess and stirring is at 40-75 [deg] C for 1.5-4 hrs.

Conductive polymers derived from aromatic heterocycles substituted by an ether-type group, method for obtaining them, devices containing these polymers, and monomers enabling such polymers to be obtained

Electrically conducting polymers containing repeat units derived from 5-membered aromatic heterocyclic monomers substituted, in the position 3 with respect to the heteroatom, by an ether-type substituent linked to the heterocycle via an alkylene radical comprising at least two carbon atoms. The invention also relates to certain monomers enabling the aforementioned conductive polymers to be obtained.

PROCESS FOR THE PREPARATION OF 3-ALCHYL-THIOPHENI-2, 5-REPLACED.

Dithienylalkylamines and process for their production

There are prepared compounds of the formula < IMAGE > (I) where >A-B- has either the structure >C(OH)-CH2- or the structure >C=CH, Alk is a straight or branched chain C1-C5- alkylene group and -NHY is < IMAGE > where R' is hydrogen, phenyl, phenyl substituted once or twice by C1-C4-alkyl groups, a C1-C4-alkoxy group or by halogen atoms, a C1-C6-alkyl group, a C1-C4-hydroxyalkyl group or a phenalkyl group whose alkyl portion consists of 1-4 carbon atoms or such a phenalkyl group containing 1 to 3 C1-C4-alkoxy group substituents. The compounds are effective in improving peripheral and cerebral circulation. There are also produced intermediate compounds of formula (II) where NHY is replaced by chlorine, bromine or iodine.

Patent JPS5035332A

Pharmaceutical compositions

Liquid crystalline compound, liquid crystal composition containing the same, and liquid crystal device using the same

Iron(ii) catalysts containing tridentate pnp ligands, their synthesis, and use thereof

The application describes catalytic materials for hydrogenation or asymmetric hydrogenation. In particular, the application describes iron(ll) complexes containing tridentate diphosphine PNP ligands useful for catalytic hydrogenation.